var title_f17_18_17696="Coronary artery dissection IVUS";
var content_f17_18_17696=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76521&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coronary artery dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 222px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After the placement of a stent in the right coronary artery there is a area of haziness, distal to the stent, seen by angiography (left panel). With intracoronary ultrasound, a dissection flap is seen protruding into the lumen of the coronary artery (right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Ziada KM, Tuzcu EM, De Franco AC, et al. Am J Cardiol 1997; 80:116.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_18_17696=[""].join("\n");
var outline_f17_18_17696=null;
var title_f17_18_17697="Proximal PA interrupt II";
var content_f17_18_17697=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proximal interruption of the right pulmonary artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A pulmonary arteriogram demonstrates the filling of the left pulmonary artery, yet also shows the absence of the right pulmonary artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_18_17697=[""].join("\n");
var outline_f17_18_17697=null;
var title_f17_18_17698="Arterial dissection";
var content_f17_18_17698=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F57866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F57866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    The progression of a dissection, thrombus development, and total vessel occlusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Mounzer Kassab.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_18_17698=[""].join("\n");
var outline_f17_18_17698=null;
var title_f17_18_17699="Infected hair follicle PI";
var content_f17_18_17699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F66769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F66769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Infected hair follicle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 391px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_18_17699=[""].join("\n");
var outline_f17_18_17699=null;
var title_f17_18_17700="Sodium thiosulfate: Drug information";
var content_f17_18_17700=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium thiosulfate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/63/11251?source=see_link\">",
"    see \"Sodium thiosulfate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/56/1924?source=see_link\">",
"    see \"Sodium thiosulfate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F222314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F222300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cyanide poisoning:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Usually given in conjunction with sodium nitrite. Administer sodium nitrite first, followed immediately by the administration of sodium thiosulfate: 12.5 g (50 mL of a 25% solution); may repeat at one-half the original dose if symptoms of cyanide toxicity return",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Monitor the patient for 24-48 hours; if symptoms return, repeat both sodium nitrite and sodium thiosulfate at one-half the original doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mechlorethamine extravasation (unlabeled route/use):",
"     </b>",
"     SubQ: 1/6 M (~4%) solution: Inject 2 mL for each mg of mechlorethamine suspected to have extravasated (Polovich, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F222309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/56/1924?source=see_link\">",
"      see \"Sodium thiosulfate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cyanide poisoning:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Usually given in conjunction with sodium nitrite. Administer sodium nitrite first, followed immediately by the administration of sodium thiosulfate. 7 g/m",
"     <sup>",
"      2",
"     </sup>",
"     or 250 mg/kg (1 mL/kg or 28-40 mL/m",
"     <sup>",
"      2",
"     </sup>",
"     of a 25% solution); maximum dose: 12.5 g (50 mL of a 25% solution); may repeat at one-half the original dose if symptoms of cyanide toxicity return",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Monitor the patient for 24-48 hours; if symptoms return, repeat both sodium nitrite and sodium thiosulfate at one-half the original doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mechlorethamine extravasation (unlabeled route/use):",
"     </b>",
"     SubQ: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F222301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14599963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; however, renal elimination of sodium thiosulfate is significant and risk of adverse effects may be increased in patients with renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14599964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F222284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 100 mg/mL (10 mL); 250 mg/mL (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 250 mg/mL (50 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F222272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F222287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Administer over 10-20 minutes using a 0.22 micron in-line filter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     SubQ (unlabeled route): Inject into the extravasation site using &le;25-gauge needle; change needle with each injection (Polovich, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F222285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Treatment of cyanide poisoning",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F222310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of mechlorethamine extravasation",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F222312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Disorientation, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, salty taste, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Bleeding time prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Warmth",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F222290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F222276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fire victims: Fire victims may present with both cyanide and carbon monoxide poisoning. In this scenario, sodium thiosulfate may be used alone to promote the clearance of cyanide. Sodium thiosulfate does, however, have a slow onset of action. Hydroxocobalamin, however, may be considered because sodium thiosulfate has a slow onset of action.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfite hypersensitivity: The presence of sulfite hypersensitivity should not preclude the use of this medication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Cyanide poisoning: Due to the risk for serious adverse effects, use with caution in patients where the diagnosis of cyanide poisoning is uncertain. However, if clinical suspicion of cyanide poisoning is high, treatment should not be delayed. Treatment of cyanide poisoning should include decontamination and supportive therapy.  Consider consultation with a poison control center at 1-800-222-1222.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Initiation of treatment: Collection of pretreatment blood cyanide concentrations does not preclude administration and should not delay administration in the emergency management of highly suspected or confirmed cyanide toxicity. Pretreatment levels may be useful as postinfusion levels may be inaccurate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Return of symptoms: Patients receiving treatment for acute cyanide toxicity must be monitored for return of symptoms for 24-48 hours; repeat treatment should be administered if symptoms return.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F222280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F222293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies of sodium thiosulfate. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Versiclear External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-1% (120 mL): $26.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sodium Thiosulfate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (10 mL): $18.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25% (50 mL): $21.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F222282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyanide poisoning: Monitor for at least 24-48 hours after administration; blood pressure and heart rate during and after infusion; hemoglobin/hematocrit; co-oximetry; serum lactate levels; venous-arterial PO",
"     <sub>",
"      2",
"     </sub>",
"     gradient; serum methemoglobin and oxyhemoglobin. Pretreatment cyanide levels may be useful diagnostically.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mechlorethamine extravasation: Monitor extravasation site for pain, blister formation, skin sloughing, arm/hand swelling/stiffness; monitor for fever, chills, or worsening pain",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Krem Ochronny z Tiosiarczanem Sodu A (PL);",
"     </li>",
"     <li>",
"      Soft Mate Consept 2 (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F222275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cyanide toxicity: Serves as a sulfur donor in rhodanese-catalyzed formation of thiocyanate (much less toxic than cyanide)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mechlorethamine extravasation: Neutralizes the reactive species of mechlorethamine; reduces the formation of hydroxyl radicals",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F222289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Thiosulfate: ~3 hours; Thiocyanate: ~3 days; Renal impairment: &le;9 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~20% to 50% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Agency for Toxic Substances and Disease Registry (ATSDR), &ldquo;Medical Management Guidelines for Hydrogen Cyanide (HCN).&rdquo; Available at",
"      <a href=\"file://www.atsdr.cdc.gov/MHMI/mmg8.pdf\" target=\"_blank\">",
"       file://www.atsdr.cdc.gov/MHMI/mmg8.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B, \"Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(2):133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/18/17700/abstract-text/12769509/pubmed\" id=\"12769509\" target=\"_blank\">",
"        12769509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Geller RJ, Barthold C, Saiers JA, et al, \"Pediatric Cyanide Poisoning: Causes, Manifestations, Management, and Unmet Needs,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 118(5):2146-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/18/17700/abstract-text/17079589/pubmed\" id=\"17079589\" target=\"_blank\">",
"        17079589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gracia R and Shepherd G, \"Cyanide Poisoning and Its Treatment,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004, 24(10):1358-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/18/17700/abstract-text/15628833/pubmed\" id=\"15628833\" target=\"_blank\">",
"        15628833",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hall AH, Dart R, and Bogdan G, &ldquo;Sodium Thiosulfate or Hydroxocobalamin for the Empiric Treatment of Cyanide Poisoning?&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2007, 49(6):806-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/18/17700/abstract-text/17098327/pubmed\" id=\"17098327\" target=\"_blank\">",
"        17098327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howland MA, &ldquo;Antidotes in Depth: Sodium and Amyl Nitrite,&rdquo;",
"      <i>",
"       Goldfrank's Toxicologic Emergencies",
"      </i>",
"      , 9th ed, Nelson LS, Hoffman RS, Lewin NA, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2011, 1519-22.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howland MA, &ldquo;Antidotes in Depth: Sodium Thiosulfate,&rdquo;",
"      <i>",
"       Goldfrank's Toxicologic Emergencies",
"      </i>",
"      , 9th ed, Nelson LS, Hoffman RS, Lewin NA, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/18/17700/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Polovich M, Whitford JN and Olsen M,",
"      <i>",
"       Chemotherapy and Biotherapy Guidelines and Recommendations for Practice",
"      </i>",
"      , 3rd ed, Pittsburgh, PA: Oncology Nursing Society, 2009.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9939 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-9B44C2D3FB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_18_17700=[""].join("\n");
var outline_f17_18_17700=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222314\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222300\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222309\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222301\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14599963\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14599964\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222284\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222272\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222287\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222285\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222310\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222312\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222290\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222276\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300072\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223035\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222280\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222293\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323882\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222282\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038829\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222275\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222289\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9939\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9939|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/63/11251?source=related_link\">",
"      Sodium thiosulfate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/56/1924?source=related_link\">",
"      Sodium thiosulfate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_18_17701="Meclofenamate: Patient drug information";
var content_f17_18_17701=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Meclofenamate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/10/21672?source=see_link\">",
"     see \"Meclofenamate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F191818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Meclomen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700782",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of very bad and sometimes deadly heart and blood vessel side effects like heart attack and stroke. The risk may be greater if you have heart disease or risks for heart disease. The risk may be greater with long-term use. Do not use this drug right before or after bypass heart surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of ulcers or bleeding from the stomach or bowel. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain, swelling, and fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease painful period (menstrual) cycles.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to meclofenamate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703559",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: GI (gastrointestinal) bleeding or ulcer disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10831 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-504D3CBC15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_18_17701=[""].join("\n");
var outline_f17_18_17701=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191818\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029882\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029884\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029883\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029888\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029889\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029891\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029886\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029887\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029892\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029893\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/10/21672?source=related_link\">",
"      Meclofenamate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_18_17702="Intermediate case 11 answer";
var content_f17_18_17702=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hyperkalemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 337px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral precordial leads showing peaked, narrow (tented) T waves and prolongation of the QRS complex (0.14 to 0.16 seconds) associated with moderate to severe hyperkalemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_18_17702=[""].join("\n");
var outline_f17_18_17702=null;
var title_f17_18_17703="Anatomy of the abdominal wall";
var content_f17_18_17703=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anatomy of the abdominal wall",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/18/17703/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/18/17703/contributors\">",
"     Jermaine E Gray, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/18/17703/contributors\">",
"     Jason S Mizell, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/18/17703/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/18/17703/contributors\">",
"     Richard Turnage, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/18/17703/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/18/17703/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/18/17703/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incision and closure of the abdominal wall are among the most frequently performed surgical procedures. The abdominal wall is defined cranially by the xiphoid process of the sternum and the costal margins, and caudally by the iliac and pubic bones of the pelvis. It extends to the lumbar spine, which joins the thorax and pelvis and is a point of attachment for some abdominal wall structures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Integrity of the anterior abdominal wall is primarily dependent upon the abdominal muscles and their conjoined tendons. These muscles assist with respiration and control the expulsive efforts of urination, defecation, coughing, and parturition. They also work with the back muscles to flex and extend the trunk at the hips, rotate the trunk at the waist, and protect viscera by becoming rigid.",
"   </p>",
"   <p>",
"    The contour of the abdomen is dependent upon age, muscle mass, muscle tone, obesity, intraabdominal pathology, parity, and posture. These factors may significantly alter topography, and become a major obstacle to proper incision selection and placement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Knowledge of the layered structure of the abdominal wall permits efficient and safe entry into the peritoneal cavity. The principal structures from exterior to interior are: skin, subcutaneous tissue, muscles with an aponeurosis, transversalis fascia, preperitoneal fat, and peritoneum. Nerves, blood vessels, and lymphatics are present throughout.",
"   </p>",
"   <p>",
"    Abdominal wall anatomy that is clinically pertinent to the surgeon, focusing primarily on the structures of the anterior abdominal wall will be reviewed. Common incisions and closure techniques, and prevention and management of wound complications are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30265?source=see_link\">",
"     \"Principles of abdominal wall incisions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=see_link\">",
"     \"Principles of abdominal wall closure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=see_link\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SKIN AND SUBCUTANEOUS TISSUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin is the largest organ of the human body. It has numerous functions, including protection against mechanical injury, prevention of bacterial invasion, and protection from the effects of ultraviolet light. Skin is loosely attached to the underlying structures of the abdomen, with the exception of the umbilicus, where the skin is tethered firmly to underlying tissue.",
"   </p>",
"   <p>",
"    Skin lines of approximately equal tension are known as Langer's lines (",
"    <a class=\"graphic graphic_figure graphicRef76685 \" href=\"UTD.htm?16/48/17155\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/3\">",
"     3",
"    </a>",
"    ]. Across the abdomen, these lines are oriented in a predominately transverse direction with a gentle curvature. Langer&rsquo;s lines are associated with the distribution of collagen and elastic fibers in the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, transverse incisions heal with a narrower, more cosmetic scar, because they are parallel to Langer's lines and have less tension, while longitudinal or oblique incisions, which traverse these lines, may heal with a broader scar.",
"   </p>",
"   <p>",
"    The subcutaneous tissue is comprised of deep and superficial adipose tissue layers separated by weak, poorly defined fibrous tissue matrices. Camper's fascia is superficial and Scarpa's fascia is deep [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/5\">",
"     5",
"    </a>",
"    ]. Camper's fascia is the superficial fatty layer that is continuous with superficial adipose, and may vary in thickness, depending upon the patient's body habitus. Scarpa's fascia is a more membranous layer that will eventually become continuous with the superficial fascia of the back and thorax. Inferiorly, this membranous layer also fuses in the midline and forms a tubular sheath for the penis or clitoris.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MUSCLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anterior abdominal wall consists primarily of the rectus muscles and associated fascia (",
"    <a class=\"graphic graphic_figure graphicRef72219 \" href=\"UTD.htm?2/35/2616\">",
"     figure 2A",
"    </a>",
"    ). Posterolateral, lateral, and the remaining anterior portion of the abdominal wall are composed of three paired, broad, flat muscles, each with an aponeurosis or tendon including the external oblique, internal oblique and transversus abdominus muscles (",
"    <a class=\"graphic graphic_figure graphicRef66280 \" href=\"UTD.htm?3/45/3798\">",
"     figure 2B",
"    </a>",
"    ). The rectus muscles are responsible for abdominal wall flexion, while the oblique muscles rotate the torso. The internal oblique and transversus abdominis muscles support and compress the abdominal contents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234643317\">",
"    <span class=\"h2\">",
"     Rectus abdominis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rectus abdominis consists of a pair of strap muscles that extend the length of the anterior abdominal wall, and are separated by the linea alba (",
"    <a class=\"graphic graphic_figure graphicRef72219 \" href=\"UTD.htm?2/35/2616\">",
"     figure 2A",
"    </a>",
"    ). These muscles arise from the symphysis pubis and the pubic crest with insertion into the fifth, sixth, and seventh costal cartilages and the xiphoid process. The rectus sheath has variable contributions from the oblique and transversus muscles. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Rectus sheath'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     External oblique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The external oblique muscle is a broad, thin muscle that arises from the surfaces of the lower eight ribs, fanning out downward to insert medially into the xiphoid process, the linea alba, and the anterior portion of the iliac crest (",
"    <a class=\"graphic graphic_figure graphicRef72219 graphicRef66280 \" href=\"UTD.htm?24/10/24746\">",
"     figure 2A-B",
"    </a>",
"    ). Its aponeurotic sheet contributes to the anterior sheath of the rectus abdominis, then fuses at the linea alba in the midline with the contralateral counterpart (",
"    <a class=\"graphic graphic_figure graphicRef77053 \" href=\"UTD.htm?28/40/29320\">",
"     figure 3",
"    </a>",
"    ). The remainder of the aponeurosis extends from the iliac spine to the pubic tubercle where it becomes the inguinal ligament.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Internal oblique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The internal oblique muscle is a broad, thin muscle that lies deep to the external oblique, with its origins from the thoracolumbar fascia, the anterior two-thirds of the iliac crest, and the lateral two-thirds of the inguinal ligament (",
"    <a class=\"graphic graphic_figure graphicRef72219 graphicRef66280 \" href=\"UTD.htm?24/10/24746\">",
"     figure 2A-B",
"    </a>",
"    ). Its aponeurotic sheet contributes to the anterior sheath of the rectus abdominis, then fuses at the linea alba in the midline with the contralateral counterpart (",
"    <a class=\"graphic graphic_figure graphicRef77053 \" href=\"UTD.htm?28/40/29320\">",
"     figure 3",
"    </a>",
"    ).The muscle fibers travel upward and forward to insert into the lower borders of the lower three ribs and their costal cartilages, the xiphoid process, the linea alba, and the symphysis pubis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Transversus abdominis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transversus abdominis muscle is a thin muscle sheet that lies deep to the internal oblique muscle. The fibers of this muscle sheet run horizontally and forward. It arises from the deep surface of the lower six costal cartilages, the lumbar fascia, iliac crest, and the lateral third of the inguinal ligament, and inserts into the xiphoid process, linea alba, and the symphysis pubis (",
"    <a class=\"graphic graphic_figure graphicRef72219 graphicRef66280 \" href=\"UTD.htm?24/10/24746\">",
"     figure 2A-B",
"    </a>",
"    ). Its aponeurotic sheet contributes to the posterior rectus sheath above the arcuate line and the anterior rectus sheath below the arcuate line (",
"    <a class=\"graphic graphic_figure graphicRef77053 \" href=\"UTD.htm?28/40/29320\">",
"     figure 3",
"    </a>",
"    ). It then fuses at the linea alba in the midline with the contralateral counterpart.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pyramidalis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pyramidalis muscle is a flat, triangular muscle at the inferior margin of the anterior abdominal wall. It originates from the superior pubic ramus, between the symphysis pubis and the pubic tubercle, and runs superomedially inserting into the linea alba. Most of the existing literature regarding this muscle focuses on whether or not it actually exists [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234642893\">",
"    <span class=\"h1\">",
"     FASCIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Rectus sheath",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rectus sheath is composed of the broad sheet-like aponeuroses of the flank muscles which enclose the rectus abdominis (and pyramidalis muscle, if present). Lateral to the rectus abdominis, the aponeuroses can be separated, but they fuse as they reach the midline (",
"    <a class=\"graphic graphic_figure graphicRef77053 \" href=\"UTD.htm?28/40/29320\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The external oblique muscle, the most superficial of the flank muscles, has a broad aponeurosis that passes anteriorly over the rectus abdominis. Beneath the external oblique, the internal oblique has a bilaminar aponeurosis that passes posterior to the rectus abdominis above the arcuate line, and anterior to the rectus below the arcuate line. The innermost abdominal muscle is the transversus abdominis. Its aponeurosis is posterior to the rectus abdominis above the arcuate line, and anterior to the rectus abdominis below the arcuate line where it fuses with the aponeurosis of the internal oblique.",
"   </p>",
"   <p>",
"    Inferior to the arcuate ligament, the aponeuroses of all three muscles form the anterior sheath. The posterior sheath is absent and the rectus lies directly on top of the transversalis fascia (",
"    <a class=\"graphic graphic_figure graphicRef77053 \" href=\"UTD.htm?28/40/29320\">",
"     figure 3",
"    </a>",
"    ). The arcuate line is the site where the inferior epigastric vessels enter the rectus sheath, travel superiorly, and converge with the superior epigastric vessels (",
"    <a class=\"graphic graphic_figure graphicRef81343 \" href=\"UTD.htm?11/30/11753\">",
"     figure 4",
"    </a>",
"    ). The arcuate line is absent in as many as 30 percent of individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Transversalis fascia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transversalis fascia is a weak fibrous layer covering the inner surface of the transversus abdominis muscles and is separated from the peritoneum by a layer of fat, commonly known as the preperitoneal fat layer. It is frequently incised off the bladder when the peritoneal cavity is opened. This layer of connective tissue forms a continuous lining for the abdominal and pelvic cavities and is continuous with the diaphragmatic fascia, the iliacus fascia, and the pelvic fascia (",
"    <a class=\"graphic graphic_figure graphicRef77053 \" href=\"UTD.htm?28/40/29320\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Linea alba",
"    </span>",
"    &nbsp;&mdash;&nbsp;The linea alba stretches from the xiphoid process to the pubic symphysis. It is defined as the fusion of the aponeuroses of the external oblique, internal oblique, and the transversus abdominis muscles (",
"    <a class=\"graphic graphic_figure graphicRef77053 \" href=\"UTD.htm?28/40/29320\">",
"     figure 3",
"    </a>",
"    ). It maintains the abdominal musculature at a certain proximity to each other. The linea tends to have its widest margin approximately 3 cm superior to the umbilicus, and has varying distances depending upon the point of reference along the abdominal wall [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PERITONEUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peritoneum is a single layer of serosa supported by a thin layer of connective tissue that lines the abdominal cavity. Five vertical folds are formed by underlying ligaments or vessels that converge at the umbilicus: the abdominal wall reflection of the bladder, which fuses with the urachus; the single middle umbilical ligament (the obliterated urachus); the paired medial umbilical ligaments (remnants of the obliterated umbilical arteries); and the lateral umbilical ligaments associated with the deep inferior epigastric vessels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     VASCULATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The blood supply of the abdominal wall is comprised of superficial and deep vascular supplies (",
"    <a class=\"graphic graphic_figure graphicRef81343 \" href=\"UTD.htm?11/30/11753\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/9\">",
"     9",
"    </a>",
"    ]. These named vessels run primarily longitudinally and may provide collateral flow channels between the subclavian artery and femoral artery when significant aortic or bilateral iliac artery obstruction is present. The superficial vasculature is located in the subcutaneous tissues and supplies the tissues superficial to the external oblique aponeurosis and the anterior rectus sheath. The muscles and tissues below these layers are supplied by the deep vessels which are located in the musculofascial layers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234642965\">",
"    <span class=\"h2\">",
"     Deep arteries",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Inferior deep epigastric arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inferior deep epigastric artery is thought to be the dominant vascular supply to the anterior abdominal wall (",
"    <a class=\"graphic graphic_figure graphicRef81343 \" href=\"UTD.htm?11/30/11753\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/9\">",
"     9",
"    </a>",
"    ]. It branches from the external iliac artery passing medially adjacent the inguinal ligament. It ascends medial to the external inguinal ring and superficial to the transversalis fascia. It then proceeds toward the umbilicus and crosses the lateral border of the rectus muscle at the arcuate line where it enters the posterior rectus sheath (",
"    <a class=\"graphic graphic_figure graphicRef51036 \" href=\"UTD.htm?25/48/26377\">",
"     figure 5",
"    </a>",
"    ). Once the artery enters the sheath, it branches extensively. It ascends within the rectus sheath to communicate with the superior deep epigastric artery. The angle between the vessels and lateral border of the rectus forms the apex of the inguinal (Hesselbach's) triangle, the base of which is the inguinal ligament.",
"   </p>",
"   <p>",
"    The musculocutaneous perforating vessels of the inferior deep epigastric artery reach and supply deeper tissue as well as the integument of the anterior abdominal wall. These perforators are particularly relevant in reconstructive surgery as an important supply for abdominal tissue flaps used [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/9\">",
"     9",
"    </a>",
"    ]. The number, location, and course of these perforators are highly variable.",
"   </p>",
"   <p>",
"    The inferior deep epigastric vessels are bounded only by loose areolar tissue below the arcuate line. Trauma to this portion of the inferior deep epigastric artery may result in considerable hemorrhage. Because hematomas commonly dissect into the retroperitoneal space, large quantities of blood may be lost before outward evidence of hematoma is detectable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Superior deep epigastric arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The superior deep epigastric artery is a terminal branch of the internal thoracic artery (",
"    <a class=\"graphic graphic_figure graphicRef81343 \" href=\"UTD.htm?11/30/11753\">",
"     figure 4",
"    </a>",
"    ). It enters the rectus sheath at the seventh costal cartilage and descends on the posterior surface of the rectus muscle (",
"    <a class=\"graphic graphic_figure graphicRef51036 \" href=\"UTD.htm?25/48/26377\">",
"     figure 5",
"    </a>",
"    ). The superior and inferior deep epigastric arteries freely anastomose with one another at the level of the umbilicus to provide a generous collateral circulation between the subclavian and external iliac arteries. These vessels communicate laterally with the intercostals, subcostal, and lumbar arteries, as well as the ascending branch of the deep circumflex iliac artery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/9\">",
"     9",
"    </a>",
"    ]. Deep branches of this vessel supply the posterior rectus sheath and the peritoneum with muscular branches and anterior perforating branches supplying skin and subcutaneous tissues. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Deep circumflex iliac arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The deep circumflex iliac artery also branches from the external iliac artery or, less frequently, from a common origin that includes the inferior epigastric artery (",
"    <a class=\"graphic graphic_figure graphicRef81343 \" href=\"UTD.htm?11/30/11753\">",
"     figure 4",
"    </a>",
"    ). Its course is lateral and vertical behind the inguinal ligament. It then turns medially at the iliac crest, where it pierces the transversus abdominis muscle. Between the transversus abdominis and internal oblique muscles, numerous connecting branches supply the lower and lateral abdominal wall. Anastomoses with the intercostal and lumbar vessels supply branches to all the flank muscles. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Musculophrenic arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The musculophrenic artery is also a branch of the internal thoracic artery (",
"    <a class=\"graphic graphic_figure graphicRef81343 \" href=\"UTD.htm?11/30/11753\">",
"     figure 4",
"    </a>",
"    ). It lies behind the costal cartilage to supply the intercostal spaces and upper abdominal wall. Anastomoses from intercostal and subcostal vessels to the deep circumflex iliac vessels occur in the deep layer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80615513\">",
"    <span class=\"h2\">",
"     Superficial arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The superficial vasculature of the abdominal wall is located in the subcutaneous tissues and consists of branches of the femoral artery, including the superficial inferior epigastric, superficial external pudendal, and superficial circumflex arteries.",
"   </p>",
"   <p>",
"    The superficial inferior epigastric vessels run diagonally in the subcutaneous tissues from the femoral artery toward the umbilicus (",
"    <a class=\"graphic graphic_figure graphicRef81343 \" href=\"UTD.htm?11/30/11753\">",
"     figure 4",
"    </a>",
"    ). They can be identified on a line between the palpable femoral pulse and umbilicus just superficial to Scarpa's fascia. As they approach the umbilicus, the arteries branch extensively.",
"   </p>",
"   <p>",
"    The external pudendal arteries have a medial and diagonal course from the femoral artery, and supply the region of the mons pubis. These vessels branch extensively as they approach the midline. Following incision, bleeding is typically heavier here than in other subcutaneous areas of the abdomen.",
"   </p>",
"   <p>",
"    The superficial circumflex iliac vessels proceed from the femoral vessels to the flank. The superficial vessels follow the general pattern of the deep vessels and arise from the iliac or femoral vessels. The exception is that the superficial inferior epigastric vessels have no superior counterparts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Veins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous drainage of the anterior abdominal wall tends to be more variable than arterial pathways; however, veins typically follow the course of arteries (",
"    <a class=\"graphic graphic_figure graphicRef81343 \" href=\"UTD.htm?11/30/11753\">",
"     figure 4",
"    </a>",
"    ). A better understanding of venous drainage systems of the anterior abdominal wall is needed for better management of abdominal flaps [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/9\">",
"     9",
"    </a>",
"    ]. Above the umbilicus, they drain to the subclavian vessels, and below the umbilicus, they drain to the external iliac vessels. Veins may be dilated in patients with obstructed blood-flow through the liver and porta hepatis. They may also be engorged in patients with large pelvic masses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234643255\">",
"    <span class=\"h2\">",
"     Collateral flow channels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several patterns of collateral flow exist in the abdominal wall due to the extensive network of vessels supplying it. The principle blood vessels involved in this collateral circulation are the internal mammary, superior epigastric, intercostals, inferior epigastric, and external iliac (",
"    <a class=\"graphic graphic_figure graphicRef81343 \" href=\"UTD.htm?11/30/11753\">",
"     figure 4",
"    </a>",
"    ). This network allows blood to bypass the occlusion of the aorta or iliac vessels, and thus, restore blood flow to the lower extremities. Case reports have described worsening of lower extremity ischemia when transverse incisions of the abdomen disrupt the abdominal wall vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234643117\">",
"    <span class=\"h1\">",
"     LYMPHATIC CHANNELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal lymphatics generally follow the course of the abdominal veins. As a general rule, the channels of the upper abdominal wall, above the level of the umbilicus, drain primarily to the anterior axillary (ie, pectoral) lymph nodes, and to a lesser extent, to the internal mammary chain (",
"    <a class=\"graphic graphic_figure graphicRef63854 \" href=\"UTD.htm?25/6/25702\">",
"     figure 6",
"    </a>",
"    ). Those of the lower abdomen, below the level of the umbilicus, drain to the inguinal nodes and then to the iliac chain of nodes. Lymphatics adjacent the umbilicus drain towards the liver through the falciform ligament. Transverse incisions are likely to disrupt lymphatic drainage to some degree. This disruption may lead to tissue swelling in the abdominal wall until collateral lymphatic drainage can be established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     NERVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intercostal and lumbar nerves enter the abdominal wall between the transversus abdominis and internal oblique muscles, and run in a generally caudal and medial direction. Each nerve innervates a dermatome, but some overlapping innervation occurs. Longitudinal incisions (except at the midline) can be expected to lead to sensory impairment inferior and medial to the level of the transected nerves.",
"   </p>",
"   <p>",
"    Although technically not nerves of the abdominal wall, the femoral nerve, the lateral femoral cutaneous nerve, and the genitofemoral nerve can also be damaged during abdominal surgery, especially with inguinal and femoral hernia repair (",
"    <a class=\"graphic graphic_figure graphicRef71423 \" href=\"UTD.htm?30/56/31624\">",
"     figure 7",
"    </a>",
"    ). The prevention of neurologic complications during the course of hernia and pelvic surgery are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3129?source=see_link\">",
"     \"Nerve injury associated with pelvic surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9465?source=see_link\">",
"     \"Inguinal and femoral hernia repair: Open techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Intercostal nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 7th to 12th intercostal nerves innervate the abdominal wall (",
"    <a class=\"graphic graphic_figure graphicRef79068 \" href=\"UTD.htm?2/61/3034\">",
"     figure 8B",
"    </a>",
"    ). Because of overlapping dermatomes, the fifth and sixth intercostal nerves can also contribute. The intercostal nerves divide into lateral cutaneous branches and anterior and posterior branches. The 10th nerve supplies the region of the umbilicus. Postoperative bulge is related to intercostal nerve injury with subsequent paralysis of abdominal wall musculature. Intercostal nerve injury can be reduced by avoiding extension of the incision into the 11th intercostal space [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Iliohypogastric nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 12th intercostal and the first lumbar nerves form the iliohypogastric nerve, which passes medial to the anterior superior iliac spine (",
"    <a class=\"graphic graphic_figure graphicRef76701 graphicRef79068 \" href=\"UTD.htm?29/3/29754\">",
"     figure 8A-B",
"    </a>",
"    ). The iliohypogastric nerve enters the abdominal wall at the transversus abdominis muscle and courses, on average, 2.1 cm medial and 0.9 cm inferior to the anterior superior iliac spine, following a linear course to terminate 3.7 cm lateral to the midline and 5.2 cm superior to pubic symphysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/12\">",
"     12",
"    </a>",
"    ]. The terminal branch courses medial and parallel to the inguinal ligament. It provides motor fibers to external oblique, internal oblique, and transversus abdominis muscles, and provides sensory fibers to the skin of the mons pubis. The anterior cutaneous branch of the iliohypogastric nerve provides sensory innervation to the skin of the upper and lateral thigh [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/13\">",
"     13",
"    </a>",
"    ]. It communicates with the ilioinguinal nerve, and provides sensory fibers to the skin overlying the external inguinal ring and symphysis. Measures to avoid nerve injury during the course of open hernia repair are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9465?source=see_link\">",
"     \"Inguinal and femoral hernia repair: Open techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Ilioinguinal nerve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ilioinguinal nerve is formed by the combination of the first and second lumbar nerves, and passes medial to the superior anterior iliac spine to supply the lower abdominal wall (",
"    <a class=\"graphic graphic_figure graphicRef76701 graphicRef79068 \" href=\"UTD.htm?29/3/29754\">",
"     figure 8A-B",
"    </a>",
"    ). On average, the proximal end of the ilioinguinal nerve enters the abdominal wall 3.1 cm medial and 3.7 cm inferior to the anterior superior iliac spine, then follows a linear course to terminate 2.7 cm lateral to the midline and 1.7 cm superior to pubic symphysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/12\">",
"     12",
"    </a>",
"    ]. The ilioinguinal nerve generally follows a course with the iliohypogastric nerve, running medially at the inguinal ligament between the transversus abdominis and internal oblique muscles. A branch of the ilioinguinal nerve accompanies the round ligament as it passes through the inguinal canal. It exits the canal at the external inguinal ring, and provides sensory fibers to the labia majora and the upper aspect of the medial thigh [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/13\">",
"     13",
"    </a>",
"    ]. Measures to avoid nerve injury during the course of open hernia are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9465?source=see_link\">",
"     \"Inguinal and femoral hernia repair: Open techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234643564\">",
"    <span class=\"h2\">",
"     Genitofemoral nerve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genitofemoral nerve has fibers from the first and second lumbar nerves, and rests on the psoas muscle lateral to the external iliac artery (",
"    <a class=\"graphic graphic_figure graphicRef76701 \" href=\"UTD.htm?14/63/15345\">",
"     figure 8A",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef79068 \" href=\"UTD.htm?2/61/3034\">",
"     figure 8B",
"    </a>",
"    ). The genital branch provides sensation to the mons pubis and labia majora. The femoral branch provides sensation to the femoral triangle [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/14\">",
"     14",
"    </a>",
"    ]. The genital branch passes within the cremasteric muscle fibers in men and in the round ligament in women, and may be encountered during open hernia surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9465?source=see_link\">",
"     \"Inguinal and femoral hernia repair: Open techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234643480\">",
"    <span class=\"h2\">",
"     Lateral femoral cutaneous nerve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second and third lumbar roots give rise to this nerve (",
"    <a class=\"graphic graphic_figure graphicRef76701 graphicRef79068 \" href=\"UTD.htm?29/3/29754\">",
"     figure 8A-B",
"    </a>",
"    ), which crosses the psoas muscle slightly above the femoral nerve and provides sensory innervation to the anterior and lateral thigh [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17703/abstract/15\">",
"     15",
"    </a>",
"    ]. It runs inferiorly and laterally toward the anterior superior iliac spine, exiting the pelvis through the lateral lacuna musculorum. It pierces the fascia approximately 2 to 3 cm below the anterior superior iliac spine. Entrapment of the lateral femoral cutaneous nerve can occur, leading to numbness; paresthesias; and pain in the anterolateral thigh, a condition known as meralgia paresthetica (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39061?source=see_link\">",
"     \"Meralgia paresthetica (lateral femoral cutaneous nerve entrapment)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234642684\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Knowledge of the anatomy of the abdominal wall is important to properly perform an abdominal incision and closure in a manner that is secure and minimizes the risk of complications such as abdominal wall hernia, bleeding, and nerve injury. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The structures comprising the abdominal wall include the skin, subcutaneous tissue, abdominal wall musculature and associated aponeuroses, preperitoneal fat, and peritoneum. The specific anatomy of the abdominal wall depends upon the location in the abdominal wall. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The anterior abdominal wall is composed of four muscles including the rectus muscles positioned anteriorly, and the oblique (external, internal) muscles and transversus abdominis muscle located anterior and posterolaterally. The rectus abdominis muscle is responsible for abdominal wall flexion. The oblique muscles provide abdominal wall rotation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Muscles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The fascial layers of the abdominal wall vary above and below the arcuate ligament. Superior to the arcuate line, the aponeuroses of the rectus and external oblique form the anterior rectus sheath and the internal oblique forms the posterior sheath. Inferior to the arcuate ligament, the aponeuroses of the rectus, external and internal oblique muscles form the anterior rectus sheath; the posterior rectus sheath is absent. (See",
"      <a class=\"local\" href=\"#H234642893\">",
"       'Fascia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The blood vessels supplying the abdominal wall originate from the internal thoracic arteries, thoracic and lumbar intercostals, the external and internal iliac arteries and common femoral arteries. Collateral flow channels may develop between the subclavian and femoral arteries when significant aortic or bilateral iliac artery obstruction is present. Venous drainage from the abdominal wall parallels the arterial supply. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Vasculature'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The lymphatics of the abdominal wall follow the course of the abdominal veins. The channels of the upper abdominal wall above the umbilicus drain primarily to the anterior axillary nodes while those below the umbilicus drain to the inguinal nodes. Transverse incisions may disrupt lymphatic drainage. (See",
"      <a class=\"local\" href=\"#H234643117\">",
"       'Lymphatic channels'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The abdominal wall is innervated by the thoracic intercostal nerves, and contributions from nerves of the lumbar plexus (L2, L3, L4) including the iliohypogastric, ilioinguinal, genitofemoral and lateral femoral cutaneous nerves. The nerves run in a predominantly transverse direction. Vertical incisions (except at the midline) can be expected to lead to sensory impairment inferior and medial to the level of the transected nerves. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Nerves'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17703/abstract/1\">",
"      Flament JB. [Functional anatomy of the abdominal wall]. Chirurg 2006; 77:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17703/abstract/2\">",
"      Ellis H. Applied anatomy of abdominal incisions. Br J Hosp Med (Lond) 2007; 68:M22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17703/abstract/3\">",
"      Langer K, Cleavage of, the curia, et al. Presented at the Meeting of the Royal Academy of Sciences, April 25, 1861. Clin Orthop 1973; 91:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17703/abstract/4\">",
"      Wong VW, Bhatt KA, Vial IN, et al. Beyond Langer's Lines: Manipulating wound mechanical forces to control hyperochic scar formation in the red Duroc pig. J Am Coll Surg 2010; 211:S77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17703/abstract/5\">",
"      TOBIN CE, BENJAMIN JA. Anatomic and clinical re-evaluation of Camper's, Scarpa's, and Colles' fasciae. Surg Gynecol Obstet 1949; 88:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17703/abstract/6\">",
"      Tokita K. Anatomical significance of the nerve to the pyramidalis muscle: a morphological study. Anat Sci Int 2006; 81:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17703/abstract/7\">",
"      Mwachaka PM, Saidi HS, Odula PO, et al. Locating the arcuate line of Douglas: is it of surgical relevance? Clin Anat 2010; 23:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17703/abstract/8\">",
"      Beer GM, Schuster A, Seifert B, et al. The normal width of the linea alba in nulliparous women. Clin Anat 2009; 22:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17703/abstract/9\">",
"      Rozen WM, Ashton MW, Taylor GI. Reviewing the vascular supply of the anterior abdominal wall: redefining anatomy for increasingly refined surgery. Clin Anat 2008; 21:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17703/abstract/10\">",
"      Krupski WC, Sumchai A, Effeney DJ, Ehrenfeld WK. The importance of abdominal wall collateral blood vessels. Planning incisions and obtaining arteriography. Arch Surg 1984; 119:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17703/abstract/11\">",
"      Gardner GP, Josephs LG, Rosca M, et al. The retroperitoneal incision. An evaluation of postoperative flank 'bulge'. Arch Surg 1994; 129:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17703/abstract/12\">",
"      Sippo WC, Burghardt A, Gomez AC. Nerve entrapment after Pfannenstiel incision. Am J Obstet Gynecol 1987; 157:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17703/abstract/13\">",
"      Whiteside JL, Barber MD, Walters MD, Falcone T. Anatomy of ilioinguinal and iliohypogastric nerves in relation to trocar placement and low transverse incisions. Am J Obstet Gynecol 2003; 189:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17703/abstract/14\">",
"      Stulz P, Pfeiffer KM. Peripheral nerve injuries resulting from common surgical procedures in the lower portion of the abdomen. Arch Surg 1982; 117:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17703/abstract/15\">",
"      Schneiderman BI, Bomze E. Paresthesias of the lateral femoral cutaneous nerve after pelvic surgery. Am Surg 1967; 33:84.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C7EAEF3114-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_18_17703=[""].join("\n");
var outline_f17_18_17703=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H234642684\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SKIN AND SUBCUTANEOUS TISSUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MUSCLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H234643317\">",
"      Rectus abdominis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      External oblique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Internal oblique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Transversus abdominis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pyramidalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H234642893\">",
"      FASCIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Rectus sheath",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Transversalis fascia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Linea alba",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PERITONEUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      VASCULATURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H234642965\">",
"      Deep arteries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Inferior deep epigastric arteries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Superior deep epigastric arteries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Deep circumflex iliac arteries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Musculophrenic arteries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H80615513\">",
"      Superficial arteries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Veins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H234643255\">",
"      Collateral flow channels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H234643117\">",
"      LYMPHATIC CHANNELS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      NERVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Intercostal nerves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Iliohypogastric nerves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Ilioinguinal nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H234643564\">",
"      Genitofemoral nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H234643480\">",
"      Lateral femoral cutaneous nerve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H234642684\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/3\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/3|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/48/17155\" title=\"figure 1\">",
"      Langers lines of the abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/35/2616\" title=\"figure 2A\">",
"      Muscles of the anterior abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/45/3798\" title=\"figure 2B\">",
"      Muscles of the lateral abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/40/29320\" title=\"figure 3\">",
"      Sectional view of the abdominal wall musculature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/30/11753\" title=\"figure 4\">",
"      Blood vessels of the anterior abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/48/26377\" title=\"figure 5\">",
"      Sagittal view of the layers of the abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/6/25702\" title=\"figure 6\">",
"      Lymphatic system PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/56/31624\" title=\"figure 7\">",
"      Nerves of the abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/63/15345\" title=\"figure 8A\">",
"      Lumbar plexus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/61/3034\" title=\"figure 8B\">",
"      Nerves of the anterior chest and abdomen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=related_link\">",
"      Abdominal surgical incisions: Prevention and treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9465?source=related_link\">",
"      Inguinal and femoral hernia repair: Open techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39061?source=related_link\">",
"      Meralgia paresthetica (lateral femoral cutaneous nerve entrapment)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3129?source=related_link\">",
"      Nerve injury associated with pelvic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=related_link\">",
"      Principles of abdominal wall closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30265?source=related_link\">",
"      Principles of abdominal wall incisions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_18_17704="EUS FNA esophageal CA";
var content_f17_18_17704=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Esophageal adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 446px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 47-year old man with progressive dysphagia had an exophytic mass lesion in the distal esophagus, which on biopsy was confirmed to be an adenocarcinoma. Panels A and B: Endoscopic ultrasonography (EUS) with the radial scanning probe demonstrated transmural invasion (T3), regional lymphadenopathy (LN), and a right pleural effusion. Panels C and D: The electronic linear scanning probe also demonstrated a T3N1 tumor with perigastric lymphadenopathy. EUS fine needle aspiration demonstrated metastatic adenocarcinoma. Note that the needle traverses normal gastric wall uninvolved with tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Norton ID, Wiersema MJ. Endoscopic ultrasound-guided fine needle aspiration biopsy. In: Endoscopic Ultrasonography. Gress F, Bhattacharya I (Eds). Blackwell Science, Malden, MA 2001. p.136. Reprinted with permission of Blackwell Science, Inc.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.blackwell-science.com\">",
"      file://www.blackwell-science.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_18_17704=[""].join("\n");
var outline_f17_18_17704=null;
var title_f17_18_17705="Cardiac rehabilitation: Exercise training and secondary prevention of coronary heart disease in older adults";
var content_f17_18_17705=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiac rehabilitation: Exercise training and secondary prevention of coronary heart disease in older adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/18/17705/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/18/17705/contributors\">",
"     Nanette K Wenger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/18/17705/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/18/17705/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/18/17705/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/18/17705/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/18/17705/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/18/17705/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary heart disease (CHD) is the leading cause of mortality in the United States in patients older than 65 years of age. Clinical evidence of CHD is present in 20 percent of the population by the age of 80 years, with a comparable prevalence in men and women. Heart failure, most often the result of CHD, is the most common discharge diagnosis for hospitalized Medicare patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States in 1993, individuals over the age of 65 accounted for more than one-half of the 1.5 million episodes of myocardial infarction (MI), 55 percent of coronary artery bypass graft surgery procedures, and 45 percent of percutaneous transluminal coronary angioplasty or other transcatheter revascularization procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elderly patients are at high risk of disability following a coronary event or hospitalization for heart failure. Complications of MI and myocardial revascularization procedures are more frequent at elderly age with prolongation of hospitalization predisposing to deconditioning.",
"   </p>",
"   <p>",
"    As a result, more than half of patients eligible for cardiac rehabilitation are older than age 65. The application of cardiac rehabilitation to elderly patients in these circumstances has gained increasing acceptance as its benefits and safety have been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13977?source=see_link\">",
"     \"Efficacy of cardiac rehabilitation in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the evidence in support of benefit of cardiac rehabilitation in older adults, utilization rates are low. In an analysis of Medicare claims for hospitalizations during 1997 in over 250,000 individuals over the age of 65, cardiac rehabilitation use was 13.9 percent in patients hospitalized for acute myocardial infarction and 31.0 percent in those who underwent coronary artery bypass graft surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/4\">",
"     4",
"    </a>",
"    ]. The very old, women, nonwhites and patients with comorbidities were less likely to have received this care.",
"   </p>",
"   <p>",
"    A 2011 review of Cardiac Care for Older Adults highlights that cardiac rehabilitation can be better utilized to reduce morbidity and mortality, to improve quality of life, increase functional capacity, reduce readmissions, and reduce healthcare costs for elderly patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/5\">",
"     5",
"    </a>",
"    ]. The multiple comorbidities and complex medication regimens are often specifically addressed within a cardiac rehabilitation setting. Although many older patients are not referred because they are deemed too frail, these are the patients that often achieve the greatest benefits.",
"   </p>",
"   <p>",
"    The findings from the American Heart Association&rsquo;s Get With the Guidelines Program identified older age and individuals with the most comorbidities as those with decreased odds of referral for cardiac rehabilitation and advocated more emphasis on increasing referral to cardiac rehabilitation to overcome the current underutilization of this modality in the secondary prevention of cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/6\">",
"     6",
"    </a>",
"    ]. In a prospective controlled study, an automatic referral strategy, combined with patient discussion, was shown to achieve the highest rates of cardiac rehabilitation referral [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/7\">",
"     7",
"    </a>",
"    ]. Institutions were encouraged to adopt such quality improvement initiatives to promote the dissemination and implementation of cardiac rehabilitation referral. This is reinforced by the findings that among Medicare beneficiaries, a strong dose-response relationship existed between the number of cardiac rehabilitation sessions attended and long-term outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/8\">",
"     8",
"    </a>",
"    ]. Attending all 36 sessions was associated with lower risk of death and myocardial infarction at four years.",
"   </p>",
"   <p>",
"    The role of cardiac rehabilitation in elderly patients with CHD is discussed here. The more general management of elderly patients with CHD is discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR CARDIAC REHABILITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Clinical Practice Guideline \"Cardiac Rehabilitation,\" released by the United States Agency for Health Care Policy and Research (AHCPR) and cosponsored by the National Heart, Lung, and Blood Institute, concluded that cardiac rehabilitation is an essential component of the contemporary management of patients with multiple presentations of CHD and with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/2\">",
"     2",
"    </a>",
"    ]. It also emphasized the added effectiveness of multifactorial cardiac rehabilitation integrated in a comprehensive approach. In the studies reviewed, elderly patients had a high adherence to exercise training, and no complications or adverse outcomes of exercise occurred.",
"   </p>",
"   <p>",
"    The benefits of cardiac rehabilitation have been confirmed in systematic reviews of the literature:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Cochrane database on exercise-based rehabilitation for CHD concluded that exercise-based cardiac rehabilitation is effective in reducing cardiac death, without clear evidence whether an exercise only or a comprehensive cardiac rehabilitation program is more beneficial [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/9\">",
"       9",
"      </a>",
"      ]. Concern was expressed that the population in this review was predominantly male, middle-aged, and low-risk, with the ethnic origin of the participants seldom reported.",
"     </li>",
"     <li>",
"      A systematic review meta-analysis of randomized controlled trials of exercise-based rehabilitation for patients with CHD showed improved cardiac and all-cause mortality and demonstrated improvement in a number of coronary risk factors [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/10\">",
"       10",
"      </a>",
"      ]. There was a favorable but insignificant trend for nonfatal MI and requirement for myocardial revascularization procedures. Elderly patients and patients with contemporary cardiac therapies were represented in the studies examined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another meta-analysis showed comparable benefits with exercise and risk reduction strategies, solely exercise, and risk reduction without supervised exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/11\">",
"     11",
"    </a>",
"    ]. Recurrent MI was reduced by 17 percent at 12 months with mortality benefit evident with longer follow-up. The authors concluded that secondary prevention programs improved processes of care, coronary risk factor profiles, functional status and quality of life.",
"   </p>",
"   <p>",
"    In 2007, the American Heart Association (AHA) and American Association of Cardiovascular and Pulmonary Rehabilitation (AACPR) published an update defining the core components of a cardiac",
"    <span class=\"nowrap\">",
"     rehabilitation/secondary",
"    </span>",
"    prevention program (",
"    <a class=\"graphic graphic_table graphicRef60257 graphicRef73513 \" href=\"UTD.htm?3/62/4067\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=see_link\">",
"     \"Components of cardiac rehabilitation and exercise prescription\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Application to older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;A specific section of the AHCPR Guideline addressed the application of cardiac rehabilitation to elderly patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/2\">",
"     2",
"    </a>",
"    ]. A statistically significant improvement in measures of exercise tolerance has been associated with exercise rehabilitation, with no significant difference between the relative improvement of older and younger patients (or between men and women) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/13\">",
"     13",
"    </a>",
"    ]. Elderly patients who participated in multifactorial cardiac rehabilitation had a significant reduction in coronary risk factors. Despite these benefits, both referral to and participation in exercise rehabilitation have been less frequent in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/13\">",
"     13",
"    </a>",
"    ], especially elderly women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/14\">",
"     14",
"    </a>",
"    ]. Comparable findings were reported in the French nationwide PREVENIR survey [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/15\">",
"     15",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The Guideline also highlighted that elderly patients were less fit than younger patients following a coronary event, in part due to their lesser fitness prior to the event [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. This is evident by the lower peak exercise capacity in elderly patients, both at entry into exercise rehabilitation and at the completion of rehabilitative exercise training. In the studies reviewed, adherence to exercise training in older adults was high, and no complications or adverse outcomes of exercise training in elderly subjects were described in any study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For all of these reasons, the Guideline recommended that elderly patients of both genders should be strongly encouraged to participate in exercise-based cardiac rehabilitation, particularly a multifactorial program. A similar recommendation was made in the 2003 Exercise and Physical Activity Scientific Statement from the AHA [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Performance measures, published in 2007, for referral to and delivery of cardiac",
"    <span class=\"nowrap\">",
"     rehabilitation/secondary",
"    </span>",
"    prevention services [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/19\">",
"     19",
"    </a>",
"    ] highlight the underuse of this integral component of cardiac care and are designed to accelerate the incorporation of this intervention into clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANTICIPATED OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early years of exercise rehabilitation, age 65 years or older was arbitrarily considered a criterion for exclusion. However, an ever increasing proportion of elderly coronary patients are currently enrolled in supervised exercise rehabilitation programs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/13,20\">",
"     13,20",
"    </a>",
"    ]. In addition, independent exercise in elderly patients is recommended with increasing frequency by physicians to aid in recovery following a coronary event, including stable angina pectoris, myocardial infarction, coronary artery bypass graft surgery, or percutaneous coronary interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/21\">",
"     21",
"    </a>",
"    ]. In older patients with heart failure and a preserved ejection fraction in whom exercise intolerance is the primary chronic symptom, exercise training improved both peak and submaximal exercise capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Substantial data support the role of physical activity in maintaining physical work capacity into old age. Exercise training results in a relative improvement in aerobic capacity among older adults that is comparable to that seen in younger subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/2\">",
"     2",
"    </a>",
"    ]. Significant increases in total work capacity may occur even in patients over the age of 75, although in these very elderly individuals the relative improvement is smaller [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Considerations for exercise in older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients being considered for an exercise program should be evaluated to determine their level of potential risk with physical activity and to determine whether any contraindications to exercise are present. In 2001 the AHA published a Scientific Statement outlining a risk classification of patients for exercise training and contraindications for exercise testing and training [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Implementation of exercise training in elderly subjects requires only modest modifications in the exercise prescription, training techniques, and standard program components that are used in younger coronary patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/25\">",
"     25",
"    </a>",
"    ]. The specific recommendations for activity levels and energy expenditure in elderly patients must include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consideration of the cardiovascular changes associated with aging [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/26\">",
"       26",
"      </a>",
"      ]. These include a decrease in maximal oxygen consumption due a loss of muscle mass [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/26\">",
"       26",
"      </a>",
"      ]; an impaired efficiency of maximal peripheral oxygen extraction; and a decline in maximal heart rate, which is compensated for by an increase in stroke volume in order to maintain cardiac output [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Changes related to physical inactivity [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/16,17,28\">",
"       16,17,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Changes reflecting the cardiac dysfunction resulting from coronary heart disease.",
"     </li>",
"     <li>",
"      Consideration of comorbidities, including arthritis and peripheral vascular disease, that may impair mobility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several distinctive features of the response to physical activity in elderly coronary patients must be appreciated if they are to attain improvement in physical work capacity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=see_link\">",
"     \"Components of cardiac rehabilitation and exercise prescription\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A greater emphasis and more time must be devoted to warm-up activities, including flexibility and range-of-motion exercises, which enable musculoskeletal and cardiorespiratory readiness for exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cool-down activities are of equal importance to allow gradual dissipation of the heat load of exercise and subsidence of exercise-induced peripheral vasodilatation which can lead to hypotension. Elderly subjects are at greater risk for the latter problem because of the delayed baroreceptor responsiveness with aging.",
"     </li>",
"     <li>",
"      The exercise heart rate returns more gradually to resting values in the elderly patient, necessitating a longer period of rest between various components of exercise or for low-intensity activity when it is alternated with periods of higher-intensity exercise.",
"     </li>",
"     <li>",
"      Aging is associated with a decrease in skin blood flow, which lowers the efficiency of sweating and temperature regulation during exercise. This warrants a reduction in the intensity of exercise for elderly patients in hot or humid environments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Exercise prescription",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aerobic training is initially begun at low intensity, eg, 2 to 3 METS, with a gradual increase in both exercise intensity and duration to limit discomfort and injury. Only mild fatigue should be engendered by an exercise training session. The elderly patient who remains asymptomatic at lower intensities of exercise and who has no contraindications to more strenuous exercise, based on the results of pretraining exercise testing, may be progressed gradually to higher, albeit still moderate, activity intensity.",
"   </p>",
"   <p>",
"    Even in previously physically active elderly individuals, musculoskeletal complications can be substantially lessened by avoidance of running, jumping, and other high-impact aerobic activities [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/30\">",
"     30",
"    </a>",
"    ]. Elderly women are more liable to experience musculoskeletal complications of high-impact activities than are elderly men.",
"   </p>",
"   <p>",
"    The absence of exercise-related angina does not exclude the presence of exercise-induced myocardial ischemia; many elderly patients have silent myocardial ischemia and dyspnea is often an anginal equivalent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42135?source=see_link\">",
"     \"Silent myocardial ischemia: Epidemiology and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Silent ischemia at pretraining exercise testing indicates what level of exercise may prove hazardous during exercise training. The intensity range recommended for exercise training should be 60 to 75 percent of the highest heart rate safely achieved at exercise testing. This exercise intensity is still an effective stimulus for aerobic metabolism and improved endurance, and is associated with greater comfort and enjoyment and fewer musculoskeletal complications than encountered at the previously recommended 70 to 85 percent heart rate range [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/30\">",
"     30",
"    </a>",
"    ]. Lower exercise intensity for training in older adults, undertaken for a longer period of time, is also characterized by greater safety during unsupervised exercise and improved adherence to long-term exercise training.",
"   </p>",
"   <p>",
"    Although the ideal exercise regimen for older adult coronary patients has not yet been determined, the exercise undertaken should be dynamic, enjoyable, easily accessible, and without adverse sequelae. Brisk regular walking is an excellent prototype of a readily accessible form of exercise designed to achieve aerobic fitness; gradual increases are recommended in both the pace and distance of walking. Further advantages are that no special equipment, facilities, exercise skills or training are required, and walking permits socialization with exercising companions. Brisk walking constitutes a substantial percentage of the lower maximal oxygen uptake of elderly patients and is therefore an effective and safe physical conditioning stimulus [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/31\">",
"     31",
"    </a>",
"    ]. In comparison, brisk walking is usually insufficient to stimulate a training effect in younger individuals, except for those who are extremely sedentary.",
"   </p>",
"   <p>",
"    Arm exercise should be added to the walking regimen since training of arm muscles is needed to effect improvement in the exercise response to arm work. Strength training, designed to improve muscle function and increase muscle mass, also enhances aerobic capacity and it is an additional component of value in the exercise rehabilitation of the elderly coronary patient [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/29,32\">",
"     29,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients have been traditionally taught to control the intensity of their exercise by pulse counting or by use of the Rating of Perceived Exertion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3687?source=see_link\">",
"     \"Exercise assessment and measurement of exercise capacity in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, my preference for elderly patients is for the \"talk test;\" patients are instructed to exercise only to an intensity that permits them to continue talking to an exercising companion.",
"   </p>",
"   <p>",
"    Enclosed shopping malls are present in many communities and they provide ideal sites for walking for elderly coronary patients who can exercise in an unsupervised setting. These venues offer a level surface in a temperature- and humidity-controlled environment.",
"   </p>",
"   <p>",
"    Exercise prescription should also include consideration of occupational, leisure, and daily life activities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=see_link&amp;anchor=H14#H14\">",
"     \"Components of cardiac rehabilitation and exercise prescription\", section on 'Lifestyle activity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Benefits of exercise in older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are number of major benefits anticipated from exercise training in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention of age-related endothelial dysfunction due to preservation or restoration of nitric oxide availability, which is possibly linked to the prevention of oxidative stress and the consequent breakdown of nitric oxide [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=see_link\">",
"       \"Endothelial dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A reduction in hemostatic factors (fibrinogen, plasma and blood viscosity, platelet count, coagulation factors VIII and IX, von Willebrand factor, fibrin D-dimer, tissue plasminogen activator antigen) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17015?source=see_link\">",
"       \"Effects of exercise on lipoproteins and hemostatic factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A decrease in the serum C-reactive protein concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=see_link\">",
"       \"C-reactive protein in cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Attenuation of age-related reductions in central arterial compliance and restoration of arterial compliance in previously sedentary, healthy middle aged and older men [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Restoration of ischemic preconditioning, which is reduced in the aging heart; the restoration of ischemic preconditioning is possibly due to an increase in norepinephrine release [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/38\">",
"       38",
"      </a>",
"      ]. This effect of exercise preserves the benefit of preinfarction angina on reducing in-hospital mortality after a myocardial infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/39\">",
"       39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=see_link\">",
"       \"Clinical implications of ischemic preconditioning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As a result of peripheral adaptation, there is a reversal of age-related decline in maximal oxygen consumption that results from a reduction in cardiac output reserve and a deconditioning effect on the distribution of cardiac output to exercising muscle [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/27,40\">",
"       27,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An improvement in physical fitness, physical work capacity, and endurance [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/23,41\">",
"       23,41",
"      </a>",
"      ]. This can prolong the duration of an active lifestyle, and may retard or obviate disability, dependency [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/16\">",
"       16",
"      </a>",
"      ], and the need for costly custodial care.",
"     </li>",
"     <li>",
"      An enhancement in flexibility, joint mobility, balance, stability, muscle strength and tone, and neuromuscular coordination which may lessen the propensity for falling and permit increased participation in the activities of daily living.",
"     </li>",
"     <li>",
"      Objectively measured physical fitness appears to be a major determinant of bone mass and bone density in older adults [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/42\">",
"       42",
"      </a>",
"      ]. Moderate-intensity exercise can retard the demineralization of bone and resultant osteoporotic fractures, a particularly important consideration for elderly women for whom osteoporosis is often a prominent problem in the absence of appropriate therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Participation in an exercise regimen at any age often encourages coronary risk reduction [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/13\">",
"       13",
"      </a>",
"      ]; the increased energy expenditure of exercise can aid in weight control and serve as an adjunct to dietary therapy, especially when smoking cessation is undertaken. Exercise also exerts a beneficial effect on CHD risk factors including obesity, hypertension, and insulin resistance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"       \"Secondary prevention of cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exercise training may be associated with improvement in self-confidence and self-image, a sense of well-being, and a lessening of anxiety, depression, and loss of motivation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/43\">",
"       43",
"      </a>",
"      ]. Although some studies describe an exercise-related improvement in cognitive function and psychomotor speed, the lessened depression associated with exercise and physical fitness may simply enable better completion of the cognitive testing modalities used in these assessments.",
"     </li>",
"     <li>",
"      Cardiac rehabilitation significantly enhanced the capability of elderly patients to live independently by improving their ability to perform common household tasks [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Improvements in both functional capacity and heart rate variability have been demonstrated [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elderly coronary patients who participate in exercise training also report an increase in their leisure activities, an increase in sexual interest and function, improved sleep status, and enhanced optimism. These multifaceted benefits can enhance the quality of life of elderly coronary patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/23,41\">",
"     23,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study assessing cardiac rehabilitation and survival in over 600,000 older adults (United States Medicare beneficiaries) hospitalized for coronary conditions or cardiac revascularization procedures, mortality rates were 21 to 34 percent lower in cardiac rehabilitation users than in nonusers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/46\">",
"     46",
"    </a>",
"    ]. These data are particularly important, given the diverse socioeconomic and clinical characteristics of the cohort, in that the benefits persisted after extensive analyses to control for potential confounding. The authors emphasize that benefits are similar in magnitude to those in published randomized controlled trials and meta-analyses that involved younger and more selected populations.",
"   </p>",
"   <p>",
"    One study of postacute, inpatient cardiac rehabilitation showed equal benefit for patients younger than 65 years of age, those 65 to 74, and those older than 75 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/47\">",
"     47",
"    </a>",
"    ]. These data reflect benefit in the population with substantial comorbidity and impaired functional status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CORONARY RISK REDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary risk factors are highly prevalent and tend to cluster at elderly age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/1\">",
"     1",
"    </a>",
"    ]. The absolute risk attributable to each of these factors increases with age because of the excess occurrence of coronary events in an elderly population. As a result, the potential benefit of risk reduction may be even greater for elderly than for younger patients. Elderly individuals are typically health-conscious and have shown themselves both willing and able to adopt healthy lifestyles.",
"   </p>",
"   <p>",
"    A 2002 AHA Scientific Statement made management recommendations for secondary prevention of CHD in older adults, with emphasis on patients &ge;75 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/48\">",
"     48",
"    </a>",
"    ]. These recommendations included lipid lowering, smoking cessation, treatment of hypertension and diabetes, weight reduction, and exercise, all of which are elements of the multifactorial approach to cardiac rehabilitation. In many respects, these recommendations are similar to those for younger patients with CHD.",
"   </p>",
"   <p>",
"    Despite the absence of large clinical trials evaluating secondary prevention of CHD specifically in older adults, many trials of secondary prevention included a substantial proportion of elderly patients. The available data suggest a benefit similar to that observed in younger individuals. Elderly participants in multifactorial cardiac rehabilitation had significant reductions in coronary risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/2\">",
"     2",
"    </a>",
"    ]. Comparable findings were reported in the French Nationwide PREVENIR survey [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the major components of secondary prevention in older adults are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of hypertension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=see_link\">",
"       \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of dyslipidemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10760?source=see_link\">",
"       \"Treatment of dyslipidemia in the older adult\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of diabetes mellitus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/42/682?source=see_link\">",
"       \"Treatment of type 2 diabetes mellitus in the elderly patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cessation of smoking. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=see_link&amp;anchor=H20#H20\">",
"       \"Cardiovascular risk of smoking and benefits of smoking cessation\", section on 'Effect of age'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Psychosocial intervention. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16250?source=see_link\">",
"       \"Psychosocial and other social factors in acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With respect to obesity, weight loss in overweight subjects produces favorable changes in a number of more powerful coronary risk factors including hyperlipidemia, hyperglycemia, and hypertension; control of obesity also encourages the maintenance of an active lifestyle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit of exercise training for weight loss in elderly patients, without nutritional intervention, is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The minimal effect of exercise alone on body weight is probably due to the low energy expenditure with exercise achieved in older adults. As a result, it is advisable to recommend more frequent and more prolonged bouts of walking as an adjunct to dietary modification in obese elderly patients with CHD.",
"   </p>",
"   <p>",
"    Suggestions from older adults for improvement of cardiac rehabilitation programs included more socialization opportunities, more variation in forms of exercise, enhancing teaching about stress management, more individual counseling, and adapting teaching strategies to cover material more slowly. The strength of physician referral was identified as the main factor influencing participation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/6/37987?source=see_link\">",
"       \"Patient information: Heart attack recovery (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21156?source=see_link\">",
"       \"Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12100?source=see_link\">",
"       \"Patient information: Heart attack recovery (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/16/23813?source=see_link\">",
"       \"Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111181702\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elderly patients (age greater than 65 years) are at high risk of disability following a coronary event or hospitalization for heart failure. Complications of MI and myocardial revascularization procedures are more frequent at elderly age with prolongation of hospitalization predisposing to deconditioning. The application of cardiac rehabilitation to elderly patients in these circumstances has gained increasing acceptance. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Strong evidence supports the use of cardiac rehabilitation in the elderly, as benefits and safety have been well documented. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Recommendations for cardiac rehabilitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The available data suggest a benefit in cardiovascular risk reduction similar to that observed in younger individuals, including a reduction in mortality. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Anticipated outcomes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The benefits of cardiac rehabilitation in the elderly extend beyond the cardiovascular system and include an improvement in physical fitness and physical work capacity as well as enhancement in flexibility, joint mobility, balance, stability, muscle strength and tone. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Benefits of exercise in older adults'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We agree with national organizations and guidelines, which support the use of cardiac rehabilitation programs for elderly patients with cardiovascular disease. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Recommendations for cardiac rehabilitation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A Presidential Advisory from the American Heart Association highlights the importance of novel approaches to the delivery of cardiac rehabilitation services to increase the access to cardiac rehabilitative care to underserved populations, including older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17705/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/1\">",
"      Wenger NK. Cardiovascular disease in the elderly. Curr Probl Cardiol 1992; 17:609.",
"     </a>",
"    </li>",
"    <li>",
"     Wenger, NK, Froelicher, ES, Smith, LK, et al. Cardiac Rehabilitation. Clinical Practice Guideline No. 17, U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Rockville, MD, AHCPR Publication No. 96-0672, October, 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/3\">",
"      Pasquali SK, Alexander KP, Peterson ED. Cardiac rehabilitation in the elderly. Am Heart J 2001; 142:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/4\">",
"      Suaya JA, Shepard DS, Normand SL, et al. Use of cardiac rehabilitation by Medicare beneficiaries after myocardial infarction or coronary bypass surgery. Circulation 2007; 116:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/5\">",
"      Forman DE, Rich MW, Alexander KP, et al. Cardiac care for older adults. Time for a new paradigm. J Am Coll Cardiol 2011; 57:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/6\">",
"      Brown TM, Hernandez AF, Bittner V, et al. Predictors of cardiac rehabilitation referral in coronary artery disease patients: findings from the American Heart Association's Get With The Guidelines Program. J Am Coll Cardiol 2009; 54:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/7\">",
"      Grace SL, Russell KL, Reid RD, et al. Effect of cardiac rehabilitation referral strategies on utilization rates: a prospective, controlled study. Arch Intern Med 2011; 171:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/8\">",
"      Hammill BG, Curtis LH, Schulman KA, Whellan DJ. Relationship between cardiac rehabilitation and long-term risks of death and myocardial infarction among elderly Medicare beneficiaries. Circulation 2010; 121:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/9\">",
"      Jolliffe JA, Rees K, Taylor RS, et al. Exercise-based rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2001; :CD001800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/10\">",
"      Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004; 116:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/11\">",
"      Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med 2005; 143:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/12\">",
"      Balady GJ, Williams MA, Ades PA, et al. Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation 2007; 115:2675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/13\">",
"      Lavie CJ, Milani RV, Littman AB. Benefits of cardiac rehabilitation and exercise training in secondary coronary prevention in the elderly. J Am Coll Cardiol 1993; 22:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/14\">",
"      Ades PA, Waldmann ML, Polk DM, Coflesky JT. Referral patterns and exercise response in the rehabilitation of female coronary patients aged greater than or equal to 62 years. Am J Cardiol 1992; 69:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/15\">",
"      Cottin Y, Cambou JP, Casillas JM, et al. Specific profile and referral bias of rehabilitated patients after an acute coronary syndrome. J Cardiopulm Rehabil 2004; 24:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/16\">",
"      Blumenthal JA, Emery CF, Madden DJ, et al. Cardiovascular and behavioral effects of aerobic exercise training in healthy older men and women. J Gerontol 1989; 44:M147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/17\">",
"      Shephard, RJ. Habitual physical activity levels and perception of exercise in the elderly. J Cardiopulm Rehabil 1989; 9:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/18\">",
"      Thompson, PD, Buchner, D, Pina, IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003; 107:e9053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/19\">",
"      Thomas RJ, King M, Lui K, et al. AACVPR/ACC/AHA 2007 performance measures on cardiac rehabilitation for referral to and delivery of cardiac rehabilitation/secondary prevention services endorsed by the American College of Chest Physicians, American College of Sports Medicine, American Physical Therapy Association, Canadian Association of Cardiac Rehabilitation, European Association for Cardiovascular Prevention and Rehabilitation, Inter-American Heart Foundation, National Association of Clinical Nurse Specialists, Preventive Cardiovascular Nurses Association, and the Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/20\">",
"      Ades PA, Waldmann ML, Gillespie C. A controlled trial of exercise training in older coronary patients. J Gerontol A Biol Sci Med Sci 1995; 50A:M7.",
"     </a>",
"    </li>",
"    <li>",
"     Wenger NK. Future directions in cardiac rehabilitation. In: Heart Disease and Rehabilitation, 3rd ed, Pollock M, Schmidt D (Eds), Human Kinetics Publishers, Champaign 1995. p.447.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/22\">",
"      Kitzman DW, Brubaker PH, Morgan TM, et al. Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail 2010; 3:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/23\">",
"      Marchionni N, Fattirolli F, Fumagalli S, et al. Improved exercise tolerance and quality of life with cardiac rehabilitation of older patients after myocardial infarction: results of a randomized, controlled trial. Circulation 2003; 107:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/24\">",
"      Fletcher GF, Balady GJ, Amsterdam EA, et al. Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 104:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/25\">",
"      Shephard RJ. The scientific basis of exercise prescribing for the very old. J Am Geriatr Soc 1990; 38:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/26\">",
"      Fleg JL, Lakatta EG. Role of muscle loss in the age-associated reduction in VO2 max. J Appl Physiol 1988; 65:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/27\">",
"      McGuire DK, Levine BD, Williamson JW, et al. A 30-year follow-up of the Dallas Bedrest and Training Study: I. Effect of age on the cardiovascular response to exercise. Circulation 2001; 104:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/28\">",
"      Jonsson PV, Lipsitz LA, Kelley M, Koestner J. Hypotensive responses to common daily activities in institutionalized elderly. A potential risk for recurrent falls. Arch Intern Med 1990; 150:1518.",
"     </a>",
"    </li>",
"    <li>",
"     Exercise in Health and Disease: Evaluation and Prescription for Prevention and Rehabilitation, 2nd ed, Pollock M, Wilmore J (Eds), WB Saunders, Philadelphia 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/30\">",
"      Pollock ML, Carroll JF, Graves JE, et al. Injuries and adherence to walk/jog and resistance training programs in the elderly. Med Sci Sports Exerc 1991; 23:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/31\">",
"      Bruce, RA, Larson, EB, Stratton, J. Physical fitness, functional aerobic capacity, aging, and response to physical training or bypass surgery in coronary patients. J Cardiopulmonary Rehabil 1989; 9:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/32\">",
"      Fiatarone MA, Marks EC, Ryan ND, et al. High-intensity strength training in nonagenarians. Effects on skeletal muscle. JAMA 1990; 263:3029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/33\">",
"      Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/34\">",
"      Taddei S, Galetta F, Virdis A, et al. Physical activity prevents age-related impairment in nitric oxide availability in elderly athletes. Circulation 2000; 101:2896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/35\">",
"      Wannamethee SG, Lowe GD, Whincup PH, et al. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 2002; 105:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/36\">",
"      Milani RV, Lavie CJ, Mehra MR. Reduction in C-reactive protein through cardiac rehabilitation and exercise training. J Am Coll Cardiol 2004; 43:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/37\">",
"      Tanaka H, Dinenno FA, Monahan KD, et al. Aging, habitual exercise, and dynamic arterial compliance. Circulation 2000; 102:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/38\">",
"      Abete P, Calabrese C, Ferrara N, et al. Exercise training restores ischemic preconditioning in the aging heart. J Am Coll Cardiol 2000; 36:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/39\">",
"      Abete P, Ferrara N, Cacciatore F, et al. High level of physical activity preserves the cardioprotective effect of preinfarction angina in elderly patients. J Am Coll Cardiol 2001; 38:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/40\">",
"      Beere PA, Russell SD, Morey MC, et al. Aerobic exercise training can reverse age-related peripheral circulatory changes in healthy older men. Circulation 1999; 100:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/41\">",
"      St&aring;hle A, Mattsson E, Ryd&eacute;n L, et al. Improved physical fitness and quality of life following training of elderly patients after acute coronary events. A 1 year follow-up randomized controlled study. Eur Heart J 1999; 20:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/42\">",
"      Pocock NA, Eisman JA, Yeates MG, et al. Physical fitness is a major determinant of femoral neck and lumbar spine bone mineral density. J Clin Invest 1986; 78:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/43\">",
"      Milani RV, Lavie CJ. Prevalence and effects of cardiac rehabilitation on depression in the elderly with coronary heart disease. Am J Cardiol 1998; 81:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/44\">",
"      Johnston M, MacDonald K, Manns P, et al. Impact of cardiac rehabilitation on the ability of elderly cardiac patients to perform common household tasks. J Cardiopulm Rehabil Prev 2011; 31:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/45\">",
"      Lai FC, Tu ST, Huang CH, Jeng C. A home-based exercise program improves heart rate variability and functional capacity among postmenopausal women with coronary artery disease. J Cardiovasc Nurs 2011; 26:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/46\">",
"      Suaya JA, Stason WB, Ades PA, et al. Cardiac rehabilitation and survival in older coronary patients. J Am Coll Cardiol 2009; 54:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/47\">",
"      Frengley JD, Sansone GR, Alba A, et al. Influence of age on rehabilitation outcomes and survival in post-acute inpatient cardiac rehabilitation. J Cardiopulm Rehabil Prev 2011; 31:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/48\">",
"      Williams MA, Fleg JL, Ades PA, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients &gt; or =75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2002; 105:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/49\">",
"      Lavie CJ, Milani RV. Effects of cardiac rehabilitation programs on exercise capacity, coronary risk factors, behavioral characteristics, and quality of life in a large elderly cohort. Am J Cardiol 1995; 76:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/50\">",
"      Dolansky MA, Moore SM, Visovsky C. Older adults' views of cardiac rehabilitation program: is it time to reinvent? J Gerontol Nurs 2006; 32:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17705/abstract/51\">",
"      Balady GJ, Ades PA, Bittner VA, et al. Referral, enrollment, and delivery of cardiac rehabilitation/secondary prevention programs at clinical centers and beyond: a presidential advisory from the American Heart Association. Circulation 2011; 124:2951.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1508 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-41275854C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_18_17705=[""].join("\n");
var outline_f17_18_17705=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H111181702\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RECOMMENDATIONS FOR CARDIAC REHABILITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Application to older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANTICIPATED OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Considerations for exercise in older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Exercise prescription",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Benefits of exercise in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CORONARY RISK REDUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H111181702\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1508\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1508|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/21/9566\" title=\"table 1A\">",
"      Core components rehab A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/3/57\" title=\"table 1B\">",
"      Core components rehab B",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=related_link\">",
"      Cardiovascular risk of smoking and benefits of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=related_link\">",
"      Clinical implications of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=related_link\">",
"      Components of cardiac rehabilitation and exercise prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17015?source=related_link\">",
"      Effects of exercise on lipoproteins and hemostatic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13977?source=related_link\">",
"      Efficacy of cardiac rehabilitation in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3687?source=related_link\">",
"      Exercise assessment and measurement of exercise capacity in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12100?source=related_link\">",
"      Patient information: Heart attack recovery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/6/37987?source=related_link\">",
"      Patient information: Heart attack recovery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/16/23813?source=related_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21156?source=related_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16250?source=related_link\">",
"      Psychosocial and other social factors in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42135?source=related_link\">",
"      Silent myocardial ischemia: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10760?source=related_link\">",
"      Treatment of dyslipidemia in the older adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=related_link\">",
"      Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/42/682?source=related_link\">",
"      Treatment of type 2 diabetes mellitus in the elderly patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_18_17706="Approach to refractory gastroesophageal reflux disease in adults";
var content_f17_18_17706=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to refractory gastroesophageal reflux disease in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/18/17706/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/18/17706/contributors\">",
"     Ronnie Fass, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/18/17706/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/18/17706/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/18/17706/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/18/17706/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/18/17706/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite treatment with proton pump inhibitors (PPIs), some patients with gastroesophageal reflux disease (GERD) continue to have reflux symptoms or endoscopic evidence of esophagitis. Approximately 10 and 40 percent of patients with GERD fail to respond symptomatically, either partially or completely, to a standard dose PPI [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Failure of the PPI treatment to resolve GERD-related symptoms has become the most common presentation of GERD among clinical gastroenterologists.",
"   </p>",
"   <p>",
"    An approach to patients with refractory GERD will be discussed here. A review of the medical management of GERD is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with GERD who do not respond to a PPI have either nonerosive reflux (NERD) or functional heartburn. In patients with NERD the pooled symptomatic response rate to PPI once daily at four weeks is 37 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In contrast, in patients with erosive esophagitis, which accounts for 30 to 40 percent of the GERD population, the pooled symptomatic response rate is 56 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The definition of refractory GERD is controversial. Because refractory GERD is a patient-driven phenomenon, PPI failure in patients who seek medical attention will exhibit different frequency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity of GERD-related symptoms. As a result, any attempt to narrow the definition of refractory GERD might exclude many true sufferers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most investigators believe that only patients with GERD who exhibit partial or lack of response to PPI twice daily should be considered as PPI failures. However, we suggest that lack of satisfactory symptomatic response to PPI once a day is sufficient to consider patients as PPI failures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     UNDERLYING MECHANISMS OF PPI FAILURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Proper dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;PPIs should be taken 30 minutes before breakfast to maximize acid inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/8\">",
"     8",
"    </a>",
"    ]. However, patients commonly take their PPI incorrectly, which may in part be because they have not received adequate instructions. One study found that only 46 percent of patients prescribed a PPI for GERD were taking it properly [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/9\">",
"     9",
"    </a>",
"    ]. Of those not taking it properly, 39 percent took it at bedtime and 4 percent as needed. Although there is no direct evidence that proper dosing can improve symptoms in patients who are not taking a PPI 30 minutes before breakfast, most authorities emphasize the need to ensure proper dosing, especially in those with refractory GERD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Compliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several surveys have demonstrated that poor compliance with PPIs is common in patients with GERD. By the end of one and six months of PPI therapy, only about 55 and 30 percent of the GERD patients, respectively, still consume their PPI once daily as initially instructed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/10\">",
"     10",
"    </a>",
"    ]. In a large, population-based study, the main factors influencing compliance were the presence or absence of symptoms, the severity of symptoms, and a personal preference about when to take treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/11\">",
"     11",
"    </a>",
"    ]. The results emphasize that GERD is a symptom-driven disease in which patients adhere to treatment instructions as long as they experience symptoms. Other general factors that affect compliance such as knowledge about the treated disorder, desire for personal control, the prescribed drug (taste, consistency, etc), side effects, number of pills per day, concomitant therapies, age, personality, socioeconomic status, and healthcare coverage may also have a role in adherence to treatment instructions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compliance should be assessed in all GERD patients who report lack of response to PPI treatment, particularly prior to ordering any evaluative test. Unfortunately, not all patients disclose that they are poorly compliant during their clinic visit. Treating physicians should repeatedly emphasize the need to consume antireflux treatment on a daily basis. It is the role of the treating physician to ensure proper compliance with the prescribed PPI through patient education about the disease and the value of compliance with treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1992772993\">",
"    <span class=\"h2\">",
"     Functional heartburn and esophageal hypersensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating patients who did not respond to PPI twice daily demonstrated that up to 58 percent of patients have functional heartburn [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Thus, functional heartburn is the most common cause for failure of PPI treatment.",
"   </p>",
"   <p>",
"    The underlying mechanisms responsible for symptoms in functional heartburn patients as defined by Rome III (burning retrosternal discomfort or pain, absence of evidence of GERD as the cause of symptoms, absence of histopathology-based esophageal motility disorders, with all three criteria fulfilled for the last three months and symptom onset at least six months prior to diagnosis) remain to be elucidated; most studies used the outdated Rome II criteria to diagnose functional heartburn. Many of these studies demonstrated increased esophageal sensitivity to chemical, mechanical, and electrical stimuli in this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. However, one report suggested that not all functional heartburn patients (based on Rome II criteria) have increased esophageal sensitivity to intraluminal stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/16\">",
"     16",
"    </a>",
"    ], and it is highly likely that functional heartburn represents a heterogeneous group of patients with different physiological mechanisms for their symptoms.",
"   </p>",
"   <p>",
"    Although a subset of patients with esophageal hypersensitivity may respond to acid suppressive therapy, this disorder is analogous to the visceral hyperalgesia described in a variety of other gastrointestinal disorders including noncardiac chest pain, functional dyspepsia, and irritable bowel syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15240?source=see_link\">",
"     \"Chest pain of esophageal origin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Weakly acidic or alkaline reflux (non-acid reflux)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies involving esophageal multichannel intraluminal impedance testing have revealed a potential role of weakly acidic or alkaline reflux in patients with persistent symptoms despite a PPI. The mechanism by which weakly acidic reflux causes GERD-related symptoms remains poorly understood. Two possible explanations have been proposed: esophageal distension by increased reflux volume and hypersensitivity to weakly acidic refluxate [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26247?source=see_link\">",
"     \"Esophageal multichannel intraluminal impedance testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1879?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of non-acid reflux\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus far, there is no evidence that weakly acidic reflux is more commonly associated with increased volume of the refluxate than acidic reflux. Although this association has been proposed, esophageal impedance does not measure the volume of the refluxate and thus cannot define the relationship between the volume and the acidity. Thus, it is impossible to determine individual thresholds for the point at which weakly acidic reflux episodes consistently provoke symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1879?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of non-acid reflux\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Residual acid reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Residual acid reflux has been documented in patients with persistent heartburn despite a PPI once or twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/13,14,20-22\">",
"     13,14,20-22",
"    </a>",
"    ]. As an example, in one study, 31 and 4 percent of GERD subjects with refractory symptoms who underwent pH testing on PPI once daily or PPI twice daily, respectively, had an abnormal test [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/23\">",
"     23",
"    </a>",
"    ]. On the other hand, several studies demonstrated that reflux characteristics in PPI failure patients are similar to those in PPI success patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/24\">",
"     24",
"    </a>",
"    ]. These studies suggest that PPI failure is primarily an esophageal hypersensitivity phenomenon. Furthermore, it appears that proximal immigration of weakly acidic reflux and the presence of gas in the refluxate are pivotal for symptom generation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bile acid reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although commonly considered as synonyms, bile reflux and non-acid reflux are different phenomena. Initial studies suggested that bile reflux probably accounts for 10 to 15 percent of non-acid reflux. However, a study using simultaneous Bilitec (a device to measure bile reflux) and impedance monitoring showed no correlation between esophageal bilirubin exposure and non-acid reflux parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. In other reports, the majority of bile reflux occurred concomitantly with acid reflux events, and thus acid rather than bile appears to be the dominant factor responsible for GERD symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, experimental data support a role for persistent bile acids in the refluxate as a potential factor involved in refractory heartburn. Although PPI therapy reduces the occurrence of acid as well as bile reflux, complete acid suppression does not guarantee the elimination of bile reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Perfusion of bile salts with non-acidic pH can still provoke heartburn [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/15\">",
"     15",
"    </a>",
"    ], and exposure of rabbit esophageal mucosa to weakly acidic solutions containing bile acids (comparable situation to patients on PPI) increased mucosal permeability and induced dilated intercellular spaces, a proposed histopathological mechanism necessary for heartburn generation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in humans also suggested a possible role for bile reflux in both symptoms and erosive esophagitis in a subset of patients with difficult to manage symptomatic reflux. In a study that included 65 patients with persistent heartburn and regurgitation while on single-dose PPI therapy, a significant number of symptoms occurred in association with bile reflux as measured by Bilitec [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/34\">",
"     34",
"    </a>",
"    ]. Furthermore, in a carefully selected group of patients with symptoms refractory to PPI therapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    20 mg three times a day significantly reduced the bile reflux exposure as well as symptoms of heartburn.",
"   </p>",
"   <p>",
"    These studies suggest a role for measurement of bile reflux in patients with persistent reflux symptoms despite PPI therapy. However, the technique is not commonly available for the practicing physician and is presently limited to less than a handful of centers with interest in gastrointestinal motility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13928?source=see_link\">",
"     \"Pathophysiology of reflux esophagitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1879?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of non-acid reflux\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10699043\">",
"    <span class=\"h2\">",
"     Nocturnal acid breakthrough",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 70 percent of patients takings PPIs twice daily have periods of gastric pH &lt;4 for more than 60 minutes, particularly at night [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/35\">",
"     35",
"    </a>",
"    ]. Nocturnal acid breakthrough (NAB) was initially proposed as a major cause of refractory GERD. In one study, for example, 24-hour pH studies during twice daily proton pump administration were compared in 76 patients with GERD and 31 healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/35\">",
"     35",
"    </a>",
"    ]. Abnormal esophageal acid exposure due to nocturnal acid breakthrough was significantly higher in patients with GERD and correlated with the severity of esophagitis (33 percent in patients with GERD and 50 percent in patients with GERD plus Barrett's esophagus versus 8 percent in controls).",
"   </p>",
"   <p>",
"    However, early reports about NAB did not attempt to demonstrate a correlation between this gastric phenomenon and nighttime GERD symptoms. Subsequent studies have shown that NAB events do not necessarily denote a temporal relationship with reflux-related symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/36\">",
"     36",
"    </a>",
"    ]. Furthermore, in one report, 71 percent of patients with GERD who did not respond to treatment with PPI twice daily experienced NAB, but only 36 percent had correlation between symptoms and NAB events [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition, there is no relationship between NAB and nocturnal heartburn [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/38\">",
"     38",
"    </a>",
"    ]. Thus, accumulating data do not support a significant role for NAB in precipitating failure of PPI treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10699057\">",
"    <span class=\"h2\">",
"     Differences in metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proton pump inhibitors are metabolized through the hepatic cytochrome system (specifically the CYP2C isoenzyme). As a result, genetically determined variability in the processes underlying drug metabolism may influence their efficacy. Patients with rapid metabolism of PPIs may have a decreased effect on gastric acidity. On the other hand, CYP2C is absent in about 3 percent of Caucasian patients and in substantially higher numbers of Asians (greater than 10 percent), potentially leading to greater suppression of gastric acidity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=see_link\">",
"     \"Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1992773116\">",
"    <span class=\"h2\">",
"     Reduced bioavailability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bioavailability of the different proton pump inhibitors varies and may be influenced by environmental conditions and manufacturing [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/39\">",
"     39",
"    </a>",
"    ]. However, for most patients, the differences in bioavailability among the proton pump inhibitors are not clinically significant during repeated dose administration since they do not translate into significant differences in the suppression of acid secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, the bioavailability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    is approximately 30 to 40 percent at doses of 20 to 40 mg. In contrast, the bioavailability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    is much higher at approximately 80 percent for doses ranging from 15 to 60 mg. Despite these differences, the two drugs have equivalent efficacy for achieving acid suppression. This was illustrated in a controlled crossover study in which meal-stimulated acid secretion was decreased by 48 and 82 percent with 15 and 30 mg lansoprazole, respectively, and by 39 and 83 percent with 20 and 40 mg of omeprazole, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The general pharmacokinetic observations may not apply to individuals in whom the bioavailability of these drugs can vary significantly [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/42\">",
"     42",
"    </a>",
"    ]. As a result, some patients may not achieve adequate acid suppression despite standard or relatively high-dose therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10699071\">",
"    <span class=\"h2\">",
"     Drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance to proton pump inhibitors is a rare condition that may be caused by mutations in the proton pump gene, a relationship that has only been described in a 1995 abstract [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/7,43\">",
"     7,43",
"    </a>",
"    ]. It is unlikely that this condition has any significant role in refractory GERD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10699078\">",
"    <span class=\"h2\">",
"     Delayed healing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete relief of heartburn with proton pump inhibitors occurs at a rate of approximately 11.5 percent per week [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/44\">",
"     44",
"    </a>",
"    ]. Thus, endoscopic healing and symptom relief are achieved within eight weeks in the majority of patients. However, patients with severe esophagitis (eg, Los Angeles C or D esophagitis) may take longer to heal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1992772901\">",
"    <span class=\"h2\">",
"     Helicobacter pylori status",
"    </span>",
"    &nbsp;&mdash;&nbsp;PPIs produce a modest increase in acid suppression in H. pylori-positive patients than H. pylori-negative patients, potentially leading to higher healing rates in patients with erosive esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The suggested underlying mechanism is migration of H. pylori proximally in the stomach to the corpus or fundus during PPI treatment. These areas of the stomach contain parietal cells, which are responsible for acid production. However, the prevalence of H. pylori infection has been rapidly declining in the United States and other developed countries, resulting in a very low background prevalence that cannot explain the large percentage of PPI failure patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/46/9959?source=see_link\">",
"     \"Helicobacter pylori and gastroesophageal reflux disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Psychological comorbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with poor correlation of symptoms with acid reflux events display a high level of anxiety and hysteria as compared with patients who demonstrate a close correlation between symptoms and acid reflux events [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/47\">",
"     47",
"    </a>",
"    ]. Anxiety and depression increase GERD-related symptoms reported in population-based studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/48\">",
"     48",
"    </a>",
"    ]. Thus, it has been proposed that patients who did not respond to PPI therapy are more likely to have psychosocial comorbidity than those who were successfully treated with a PPI [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other diseases that should be considered in patients with refractory GERD are achalasia, esophageal cancer, esophageal stricture, other causes of esophagitis, and gastric stasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with achalasia may develop heartburn as a result of fermentation of retained food in the esophagus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=see_link\">",
"       \"Clinical manifestations and diagnosis of achalasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with distal esophageal cancer may continue to have symptoms and have ulceration mimicking peptic esophagitis on endoscopy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=see_link&amp;anchor=H2#H2\">",
"       \"Diagnosis and staging of esophageal cancer\", section on 'Diagnostic testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who have dysphagia associated with reflux may continue to be symptomatic despite adequate acid suppression if they have developed a stricture. Relief usually accompanies adequate dilation.",
"     </li>",
"     <li>",
"      Patients who are taking nonsteroidal antiinflammatory drugs (NSAIDs) can experience pyrosis and may be more susceptible to acid-related esophageal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"       \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with rumination syndrome may be thought to have GERD. However, questioning regarding the symptoms of rumination syndrome should distinguish between the two disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link&amp;anchor=H12#H12\">",
"       \"Etiology and diagnosis of delayed gastric emptying\", section on 'Rumination syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In addition to acid, a variety of caustic and infectious causes are associated with esophagitis. Examples include pill-induced esophagitis, caustic ingestion, Candida, herpes, and radiation. These causes should be excluded. (See appropriate topic reviews.)",
"     </li>",
"     <li>",
"      Patients who have impaired gastric emptying are predisposed to reflux. Symptoms may be improved after appropriate treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link\">",
"       \"Treatment of delayed gastric emptying\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Eosinophilic esophagitis in adults is commonly associated with dysphagia while only about one-third of patients report classic heartburn symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/52-57\">",
"       52-57",
"      </a>",
"      ]. Heartburn alone is uncommon. The relationship between eosinophilic esophagitis and reflux is complex and the prevalence of eosinophilic esophagitis in patients with heartburn refractory to PPIs has ranged between 0.9 percent and 8.8 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sensitization to foods appears to be common among patients with refractory GERD. In one study of 65 patients with refractory GERD, sensitization to foods was present in 18 patients (28 percent) based upon the results of skin testing [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/58\">",
"       58",
"      </a>",
"      ]. Eosinophils were found in the esophageal mucosa of patients who were food sensitized more often than in patients who were not (38 versus 7 percent), but only one patient was diagnosed with eosinophilic esophagitis. Fifteen of the food sensitized patients followed a six-week restriction diet, with symptom improvement in 12 patients (80 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"       \"Clinical manifestations of food allergy: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In one study, patients with GERD who also had irritable bowel syndrome (IBS) perceived their symptoms as more severe and tended not to achieve the same degree of symptom improvement during PPI treatment compared with patients with GERD without IBS [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic evaluation for refractory GERD should be considered in patients after an evaluation of proper compliance and reinforcement of lifestyle modification (see",
"    <a class=\"local\" href=\"#H1992771493\">",
"     'Optimizing therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1992771500\">",
"     'Lifestyle modifications'",
"    </a>",
"    below). In patients without alarm symptoms (eg, dysphagia, odynophagia, anorexia, weight loss, or upper GI bleeding), an empiric trial of doubling the dose of a PPI or switching to a different PPI should be considered prior to initiating diagnostic testing (",
"    <a class=\"graphic graphic_algorithm graphicRef70106 \" href=\"UTD.htm?33/56/34703\">",
"     algorithm 1",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Treatment of residual acid reflux'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Upper endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who fail a PPI once daily and also have alarm symptoms should undergo upper endoscopy. The value of endoscopy in patients with refractory GERD without alarm symptoms is limited; there is no evidence that PPI failure is associated with an increased likelihood of a life-threatening esophageal or gastric lesion. There is some evidence that if endoscopy is performed, biopsies assessing for dilated intercellular spaces might help to separate true refluxers from those who have functional heartburn [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Esophageal pH testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who fail PPI twice daily should undergo esophageal pH testing. The traditional pH test is abnormal in a third of the patients who failed PPI once daily but in only 7 percent of those who failed PPI twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/23\">",
"     23",
"    </a>",
"    ]. The pH test can be performed while off treatment in patients without typical GERD symptoms, to determine if reflux is the cause of their symptoms or while on treatment and together with impedance testing in patients with a partial response to PPIs to determine if there is continued pathological acid or non-acid exposure despite a PPI [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A role for wireless pH capsule in patients who failed PPI has been proposed primarily because of the advantage of multiple days recording. The technique may be used over a period of four days (two on and two off treatment) in patients who failed PPI treatment. However, both the wireless pH capsule and traditional pH probe do not measure weakly acidic or alkaline reflux and thus have been replaced by esophageal impedance and pH monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/61\">",
"     61",
"    </a>",
"    ]. The latter is the currently preferred diagnostic strategy in patients who failed PPI given twice daily. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26247?source=see_link\">",
"     \"Esophageal multichannel intraluminal impedance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Esophageal impedance testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal esophageal impedance testing combined with pH monitoring while on therapy in patients with a partial response to PPIs can determine if there is continued pathological acid or non-acid exposure despite a PPI [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/60\">",
"     60",
"    </a>",
"    ]. It can also help predict which patients have acid reflux off therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26247?source=see_link\">",
"     \"Esophageal multichannel intraluminal impedance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1992771420\">",
"    <span class=\"h2\">",
"     Esophageal manometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of esophageal manometry in refractory GERD is very limited. This is primarily because most of treatment failure patients have NERD or functional heartburn. However, in those with suspected achalasia and in all patients undergoing surgery for GERD, esophageal manometry should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16568?source=see_link\">",
"     \"Motility testing: When does it help?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1992771471\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of patients with GERD refractory to proton pump inhibitors should begin with an assessment of compliance and reinforcement of lifestyle modification. In patients who failed PPI once per day, initial options include switching to another PPI or doubling the PPI dose (",
"    <a class=\"graphic graphic_algorithm graphicRef70106 \" href=\"UTD.htm?33/56/34703\">",
"     algorithm 1",
"    </a>",
"    ). Detailed physiologic studies of patients with GERD who failed PPI therapy have suggested that three different types of gastroesophageal reflux are clinically relevant: acidic, weakly",
"    <span class=\"nowrap\">",
"     acidic/alkaline",
"    </span>",
"    reflux, and duodenogastroesophageal reflux. Therapeutic options based on the pH of the refluxate are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1992771493\">",
"    <span class=\"h2\">",
"     Optimizing therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of proper compliance and adequate dosing time should be the first management step when assessing patients with heartburn who are not responding to PPI before instituting any other intervention. As noted above, patients should be instructed to take a PPI 30 minutes before a meal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1992771500\">",
"    <span class=\"h2\">",
"     Lifestyle modifications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific value of lifestyle modifications in GERD patients who failed PPI treatment has yet to be elucidated. In patients with persistent heartburn despite PPI treatment, it is reasonable to recommend avoidance of specific lifestyle activities that have been identified by patients or physicians to trigger GERD-related symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link&amp;anchor=H2#H2\">",
"     \"Medical management of gastroesophageal reflux disease in adults\", section on 'Lifestyle modifications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Treatment of residual acid reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who failed PPI once a day, there are several potential therapeutic strategies aimed at reducing residual acid reflux.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1992771592\">",
"    <span class=\"h3\">",
"     Adjustment of proton pump inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Switching to another PPI or doubling the PPI dose are options in treating residual acid reflux in patients on once daily PPI.",
"   </p>",
"   <p>",
"    We usually double the dose for eight weeks before considering an alternative PPI, although either option is effective, as illustrated by the findings of a study of patients who failed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    30 mg once daily and were randomly assigned to either double-dose lansoprazole or 40 mg once daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/63\">",
"     63",
"    </a>",
"    ]. Single-dose esomeprazole was as effective as double-dose lansoprazole in the percentage of heartburn free days and symptom score for heartburn, acid regurgitation, and epigastric pain. There are no other randomized controlled trials that have compared switching to other PPI brands versus increasing the dose.",
"   </p>",
"   <p>",
"    Doubling the PPI dose has become a common practice in patients with GERD who failed PPI once daily. In a report of patients with erosive esophagitis, doubling the PPI dose increased the healing rate by 6 percent but had no impact on symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/64\">",
"     64",
"    </a>",
"    ]. In other reports of patients with symptomatic GERD who failed PPI once a day, doubling the PPI dose increased the rate of overall symptom improvement by 22 to 26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also support for doubling the PPI dose in patients with functional heartburn. Patients with the sensitive esophagus (normal endoscopy and pH test but positive symptom index) were more likely to respond to PPI twice a day [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/66\">",
"     66",
"    </a>",
"    ]. There is no evidence to support further escalation of the PPI dose in those who failed PPI twice daily.",
"   </p>",
"   <p>",
"    When doubling the PPI dose, one PPI should be given before breakfast and the other before dinner. The support for splitting the dose originates primarily from physiologic studies demonstrating improved control of intragastric pH when one PPI is given in the A.M. and the other in the P.M. compared with both PPIs being given before breakfast [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Bedtime H2 receptor antagonist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another strategy that has been suggested is to add a bedtime H2 receptor antagonist (H2RA) only in patients who failed PPI twice daily. The hope is to significantly reduce nocturnal acid breakthrough in patients who failed PPI twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/68\">",
"     68",
"    </a>",
"    ]. However, the enthusiasm about the value of adding H2RA at bedtime has been subsequently tempered by studies demonstrating rapid development of tolerance to H2RA; in one such report there was no difference in gastric acid suppression between PPI twice daily and PPI twice daily plus H2RA at bedtime after one week of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/69\">",
"     69",
"    </a>",
"    ]. Similarly, subsequent studies evaluating the efficacy of an H2RA added to a PPI have questioned the benefit of adding a nighttime H2RA [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/69-72\">",
"     69-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, observational data and clinical experience have suggested that long-term use of an H2RA at bedtime can be clinically beneficial, at least for some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/73\">",
"     73",
"    </a>",
"    ]. Thus, a nighttime H2RA may be an option in patients who do not respond to PPI twice daily; if clinical tolerance has been encountered, then using the H2RA intermittently or on demand could theoretically be helpful.",
"   </p>",
"   <p>",
"    In patients with persistent acid reflux after the addition of an H2RA, antacids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/16/27910?source=see_link\">",
"     aluminum hydroxide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/6/31847?source=see_link\">",
"     magnesium hydroxide",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    may provide some relief.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Treatments aimed at reducing weakly acidic reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of compounds reduce the rate of transient lower esophageal sphincter relaxation (TLESR) and thus the number of reflux events. However, only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    , a gamma-aminobutyric acid B receptor agonist, was introduced into the clinical arena as a potential add-on treatment for patients who failed PPI treatment (once or twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. The drug reduced TLESR rate by 40 to 60 percent, reduced reflux episodes by 43 percent, increased lower esophageal sphincter basal pressure, and accelerated gastric emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. In other reports, baclofen significantly reduced weakly acidic and bile reflux and gastroesophageal reflux-related symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. In patients with persistent heartburn despite PPI treatment, doses up to 20 mg three times daily have been used [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the drug crosses the blood-brain barrier, a variety of central nervous system (CNS)-related side effects may occur. They primarily include somnolence, confusion, dizziness, lightheadedness, drowsiness, weakness, and trembling. The side effects are an important limiting factor in the routine usage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    in clinical practice. However, several baclofen-like prototypes with better clinical and side-effect profiles are currently in development. In a double-blind, placebo-controlled, randomized phase IIA trial, treatment with lesogaberan, a novel gamma-aminobutyric acid B receptor agonist, resulted in significantly improved heartburn and regurgitation symptoms; however, the proportion of responders was small (16 versus 8 percent). Lesogaberan was well tolerated with adverse events that were comparable to the placebo group (45 versus 37 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    in patients with refractory GERD on PPI twice daily who demonstrate symptoms associated with non-acidic reflux on an esophageal impedance pH study. If access to an esophageal impedance pH study is unavailable, we suggest an empiric trial of baclofen in those whose symptoms are primarily regurgitation. We usually begin by giving 10 mg twice daily, which can be increased slowly to 20 mg three times daily while carefully monitoring for side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Treatment of esophageal hypersensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no large studies that have specifically evaluated the value of visceral pain modulators in GERD patients with persistent heartburn despite PPI treatment. However, the use of such agents is potentially attractive since, as noted above, most patients who fail PPI treatment have NERD and more than one-half of these patients do not have pathological reflux on pH testing [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pain modulators such as tricyclic antidepressants,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    , and selective serotonin reuptake inhibitors have all been shown to improve esophageal pain in patients with noncardiac chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/13,81,82\">",
"     13,81,82",
"    </a>",
"    ]. It is believed that these agents confer their visceral analgesic effect by acting at the central nervous system",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sensory afferents level. The pain modulators are used in non-mood-altering doses, and they presently provide a therapeutic alternative until more novel and esophageal-specific compounds are available.",
"   </p>",
"   <p>",
"    In patients with refractory GERD who have an unremarkable esophageal impedance pH study and in patients with non-acid reflux, we suggest a trial of visceral analgesics, such as a tricyclic antidepressant, selective serotonin uptake inhibitor, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    . If access to esophageal impedance pH is not available, and patients primarily report heartburn, we generally begin with a trial of an H2 receptor antagonist (H2RA) at bedtime, suggesting it be used intermittently to avoid tachyphylaxis. In those who do not respond, we then suggest a trial of a tricyclic antidepressant, trazodone, or a selective serotonin reuptake inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Treatment of delayed gastric emptying",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have assessed the value of the current therapeutic approach to delayed gastric emptying in patients with GERD who have failed PPI therapy. However, it is likely that these patients will also complain about other dyspeptic symptoms (nausea, abdominal pain, early satiety, and vomiting) related to slow gastric motor activity. As a result, it is conceivable that dietary and medical treatment aimed at improving delayed gastric emptying will improve patients' overall symptoms including those related to GERD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link\">",
"     \"Treatment of delayed gastric emptying\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Surgical treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antireflux surgery should be considered in patients who require high doses of proton pump inhibitors to control symptoms, particularly in young patients who may require lifelong therapy. Whether surgery is beneficial in patients who have failed PPI therapy remains controversial. Surgery is not recommended in patients who do not respond to PPI therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=see_link\">",
"     \"Surgical management of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study, refractory GERD was the most common (88 percent) indication for antireflux surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/83\">",
"     83",
"    </a>",
"    ] and a number of surgical studies have suggested that fundoplication may be of benefit in patients with refractory GERD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/13,83\">",
"     13,83",
"    </a>",
"    ]. However, many of these reports had important methodologic limitations such as variable definitions of \"refractory\" GERD and clinical endpoints and accounting for dropouts. Furthermore, patients who have undergone fundoplication may continue to use antisecretory medications (ranging from 10 percent to almost two-thirds of patients in a systematic review) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/84\">",
"     84",
"    </a>",
"    ]. The predictors of successful outcomes following fundoplication also remain poorly defined [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another surgical approach is laparoscopic sphincter augmentation using a device comprised of a string of magnetized beads [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/86-89\">",
"     86-89",
"    </a>",
"    ]. The device is implanted at the lower esophageal sphincter to maintain closure of a weak lower esophageal sphincter, preventing reflux. The beads then separate when the patient swallows to allow passage of a food or liquid bolus. &nbsp;In one prospective study, 100 patients with GERD that was partially responsive to PPIs underwent implantation of a magnetic esophageal sphincter device [",
"    <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/88\">",
"     88",
"    </a>",
"    ]. At three-year follow-up, a 50 percent or greater reduction in esophageal acid exposure was achieved in 64 percent of patients and 87 percent of patients reported complete cessation of PPI use. The most frequent adverse event was dysphagia, which occurred in 68 percent of patients. Serious side effects occurred in six percent of individuals. However, randomized controlled trials are needed to confirm these results and to assess the long-term safety of magnetic devices to treat refractory GERD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Other therapeutic approaches",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The role of bile acid binders such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"       cholestyramine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"       sucralfate",
"      </a>",
"      in patients with GERD who failed PPI treatment remains unclear. Reducing bile reflux in this patient population is desirable, but it is unclear if any of the currently available bile acid binders are sufficiently effective to improve symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acupuncture has been evaluated in patients with GERD who failed PPI once daily [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/90\">",
"       90",
"      </a>",
"      ]. When compared to doubling the PPI dose (standard of care), adding acupuncture was significantly better in controlling regurgitation, daytime and nighttime heartburn. The potential benefit may be related to treatment of visceral pain but more data are needed.",
"     </li>",
"     <li>",
"      There are no rigorous studies that have evaluated the value of screening for psychological comorbidity in patients who failed PPI treatment. However, one study demonstrated that response to PPI treatment may depend upon the level of psychological distress [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/49\">",
"       49",
"      </a>",
"      ]. Similarly, a systematic review found that psychological comorbidities were associated with worse outcomes after fundoplication [",
"      <a class=\"abstract\" href=\"UTD.htm?17/18/17706/abstract/48\">",
"       48",
"      </a>",
"      ]. More data are needed to determine what role, if any, treatment of psychological disturbances has in the management of patients with refractory GERD.",
"     </li>",
"     <li>",
"      Multiple endoscopic approaches for treating GERD have been developed, though none is currently in wide-spread use. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25688?source=see_link\">",
"       \"Endoscopic therapy for gastroesophageal reflux disease: Sewing and full-thickness plication techniques\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12263?source=see_link\">",
"       \"Radiofrequency treatment for gastroesophageal reflux disease (the Stretta&reg; procedure)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The definition of \"refractory\" GERD is unsettled. Some authorities suggest that it represents patients who have a lack of a clinical response to a PPI given twice daily. We consider that lack of satisfactory symptomatic response to PPI once a day is sufficient to consider patients as PPI failures. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with GERD who do not respond to a PPI have nonerosive reflux disease (NERD) or functional heartburn. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who have persistent symptoms despite taking a PPI once daily, we suggest the following approach (",
"      <a class=\"graphic graphic_algorithm graphicRef70106 \" href=\"UTD.htm?33/56/34703\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ensure proper dosing of a PPI. In particular, patients should be asked if they are taking a PPI 30 minutes before a meal and if they are taking it regularly.",
"     </li>",
"     <li>",
"      Suggest lifestyle modifications, particularly if patients note an association with symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link&amp;anchor=H2#H2\">",
"       \"Medical management of gastroesophageal reflux disease in adults\", section on 'Lifestyle modifications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Consider alternative diagnoses including an esophageal motility disorder, use of drugs (such as NSAIDs) that can lead to pyrosis, Candida esophagitis in patients with risk factors, gastroparesis, and eosinophilic esophagitis in patients who have dysphagia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with refractory GERD who have not already undergone upper endoscopy and who have alarm symptoms such as dysphagia, odynophagia, anorexia, weight loss, and upper GI bleed, we suggest performing an upper endoscopy. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Upper endoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with persistent symptoms despite the above, we suggest giving a PPI twice daily (30 minutes before breakfast and 30 minutes before dinner) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Switching to a different PPI may be an equally effective alternative. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Treatment of residual acid reflux'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If symptoms continue despite the above (twice daily PPI), we suggest performing esophageal impedance and pH testing where available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26247?source=see_link\">",
"       \"Esophageal multichannel intraluminal impedance testing\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with persistent acid reflux on esophageal impedance and pH testing or when testing is unavailable and patients primarily report heartburn, we suggest adding a bedtime H2RA (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If clinical tolerance develops, H2RA can be used intermittently or on demand. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Bedtime H2 receptor antagonist'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with refractory GERD on PPI twice daily who demonstrate symptoms associated with non-acidic reflux on an esophageal impedance pH study, we suggest a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"       baclofen",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If access to an esophageal impedance pH study is unavailable, we suggest an empiric trial of baclofen in those whose symptoms are primarily regurgitation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We usually begin by giving 10 mg twice daily, which can be increased slowly to 20 mg three times daily. Patients should be monitored for side effects such as somnolence, confusion, dizziness, lightheadedness, drowsiness, weakness, and trembling.",
"      <br/>",
"      <br/>",
"      We have observed that this subset of patients (ie, symptoms primarily related to regurgitation despite treatment with a PPI twice daily) may benefit from a Nissen fundoplication. However, only patients who underwent esophageal impedance and pH study should be considered for antireflux surgery. Such patients should also be advised that there are limited data that have established the efficacy of fundoplication in this setting. They should also be advised of the potential morbidity after fundoplication. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1879?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of non-acid reflux\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=see_link\">",
"       \"Surgical management of gastroesophageal reflux in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with refractory GERD who have a normal esophageal impedance and pH study or even those with non-acid reflux, we suggest a trial of visceral analgesics, such as a tricyclic antidepressant, selective serotonin uptake inhibitor, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If access to esophageal impedance pH is not available, patients primarily report heartburn and have failed the addition of an H2RA, we suggest a trial of a tricyclic antidepressant, trazodone, or a selective serotonin reuptake inhibitor.",
"     </li>",
"     <li>",
"      In patients with persistent symptoms despite the above and who have symptoms suggestive of delayed gastric emptying (nausea, abdominal pain, early satiety, and vomiting), we suggest treatment aimed at improving gastric emptying (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link\">",
"       \"Treatment of delayed gastric emptying\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/1\">",
"      Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003; 98:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/2\">",
"      Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998; 10:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/3\">",
"      Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs study. J Clin Outcomes Manag 2000; 7:29.",
"     </a>",
"    </li>",
"    <li>",
"     The Gallup Organization I. The 2000 Gallup study of consumers' use of stomach relief products, The Gallup Organization, Princeton, NJ 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/5\">",
"      Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/6\">",
"      Fass R, Sampliner RE. Barrett's oesophagus: optimal strategies for prevention and treatment. Drugs 2003; 63:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/7\">",
"      Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs 2007; 67:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/8\">",
"      Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000; 14:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/9\">",
"      Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006; 23:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/10\">",
"      Fass R, Gasiorowska A. Refractory GERD: what is it? Curr Gastroenterol Rep 2008; 10:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/11\">",
"      Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999; 49:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/12\">",
"      Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next? Aliment Pharmacol Ther 2005; 22:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/13\">",
"      Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006; 55:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/14\">",
"      Sharma N, Agrawal A, Freeman J, et al. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol 2008; 6:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/15\">",
"      Siddiqui A, Rodriguez-Stanley S, Zubaidi S, Miner PB Jr. Esophageal visceral sensitivity to bile salts in patients with functional heartburn and in healthy control subjects. Dig Dis Sci 2005; 50:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/16\">",
"      Shapiro M, Green C, Bautista JM, et al. Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid. Am J Gastroenterol 2006; 101:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/17\">",
"      Mirbagheri SA, Sadeghi A, Amouie M, et al. Pyloric injection of botulinum toxin for the treatment of refractory GERD accompanied with gastroparesis: a preliminary report. Dig Dis Sci 2008; 53:2621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/18\">",
"      Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut 1995; 37:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/19\">",
"      Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009; 58:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/20\">",
"      Bautista JM, Wong WM, Pulliam G, et al. The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications. Dig Dis Sci 2005; 50:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/21\">",
"      Karamanolis G, Vanuytsel T, Sifrim D, et al. Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci 2008; 53:2387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/22\">",
"      Koek GH, Tack J, Sifrim D, et al. The role of acid and duodenal gastroesophageal reflux in symptomatic GERD. Am J Gastroenterol 2001; 96:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/23\">",
"      Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005; 100:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/24\">",
"      Gasiorowska A, Navarro-Rodriguez T, Wendel C, et al. Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily. Am J Gastroenterol 2009; 104:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/25\">",
"      Tutuian R, Vela MF, Hill EG, et al. Characteristics of symptomatic reflux episodes on Acid suppressive therapy. Am J Gastroenterol 2008; 103:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/26\">",
"      Pace F, Sangaletti O, Pallotta S, et al. Biliary reflux and non-acid reflux are two distinct phenomena: a comparison between 24-hour multichannel intraesophageal impedance and bilirubin monitoring. Scand J Gastroenterol 2007; 42:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/27\">",
"      Vaezi MF, Lacamera RG, Richter JE. Validation studies of Bilitec 2000: an ambulatory duodenogastric reflux monitoring system. Am J Physiol 1994; 267:G1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/28\">",
"      Sifrim D. Acid, weakly acidic and non-acid gastro-oesophageal reflux: differences, prevalence and clinical relevance. Eur J Gastroenterol Hepatol 2004; 16:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/29\">",
"      Marshall RE, Anggiansah A, Owen WA, Owen WJ. The relationship between acid and bile reflux and symptoms in gastro-oesophageal reflux disease. Gut 1997; 40:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/30\">",
"      Champion G, Richter JE, Vaezi MF, et al. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology 1994; 107:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/31\">",
"      Netzer P, Gut A, Brundler R, et al. Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis. Aliment Pharmacol Ther 2001; 15:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/32\">",
"      Todd JA, Basu KK, de Caestecker JS. Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus. Aliment Pharmacol Ther 2005; 21:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/33\">",
"      Farre R, Van Malenstein MH, de Vos R, et al. Weakly acidic solutions containing pepsin and bile acids can increase significantly esophageal mucosa permeability (abstract). Gastroenterology 2007; 132(4 Suppl 2):S1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/34\">",
"      Tack J, Koek G, Demedts I, et al. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004; 99:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/35\">",
"      Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/36\">",
"      Fouad YM, Katz PO, Castell DO. Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther 1999; 13:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/37\">",
"      Orr WC, Harnish MJ. The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity. Aliment Pharmacol Ther 2003; 17:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/38\">",
"      Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/39\">",
"      Storpirtis S, Rodrigues D. In vitro evaluation of dissolution properties and degradation products of omeprazole in enteric-coated pellets. Drug Dev Ind Pharm 1998; 24:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/40\">",
"      Andersson T, Andr&eacute;n K, Cederberg C, et al. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 1990; 29:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/41\">",
"      Dammann HG, Fuchs W, Richter G, et al. Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Aliment Pharmacol Ther 1997; 11:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/42\">",
"      Gerloff J, Mignot A, Barth H, Heintze K. Pharmacokinetics and absolute bioavailability of lansoprazole. Eur J Clin Pharmacol 1996; 50:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/43\">",
"      Leite L, Lambrecht N, Sachs G, et al. Is omeprazole resistance due to mutations of cysteine 813 or 822 in the acid pump? (abstract). Gastroenterology 1995; 108:A147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/44\">",
"      Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/45\">",
"      Verd&uacute; EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/46\">",
"      Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/47\">",
"      Rubenstein JH, Nojkov B, Korsnes S, et al. Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/48\">",
"      Mizyed I, Fass SS, Fass R. Review article: gastro-oesophageal reflux disease and psychological comorbidity. Aliment Pharmacol Ther 2009; 29:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/49\">",
"      Nojkov B, Rubenstein JH, Adlis SA, et al. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/50\">",
"      Sope&ntilde;a F, Lanas A, S&aacute;inz R. Esophageal motility and intraesophageal pH patterns in patients with esophagitis and chronic nonsteroidal anti-inflammatory drug use. J Clin Gastroenterol 1998; 27:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/51\">",
"      El-Serag HB, Sonnenberg A. Association of esophagitis and esophageal strictures with diseases treated with nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 1997; 92:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/52\">",
"      Remedios M, Campbell C, Jones DM, Kerlin P. Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate. Gastrointest Endosc 2006; 63:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/53\">",
"      Straumann A, Spichtin HP, Grize L, et al. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 2003; 125:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/54\">",
"      Croese J, Fairley SK, Masson JW, et al. Clinical and endoscopic features of eosinophilic esophagitis in adults. Gastrointest Endosc 2003; 58:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/55\">",
"      Potter JW, Saeian K, Staff D, et al. Eosinophilic esophagitis in adults: an emerging problem with unique esophageal features. Gastrointest Endosc 2004; 59:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/56\">",
"      Zimmerman SL, Levine MS, Rubesin SE, et al. Idiopathic eosinophilic esophagitis in adults: the ringed esophagus. Radiology 2005; 236:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/57\">",
"      Kapel RC, Miller JK, Torres C, et al. Eosinophilic esophagitis: a prevalent disease in the United States that affects all age groups. Gastroenterology 2008; 134:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/58\">",
"      Pomiecinski F, Yang AC, Navarro-Rodrigues T, et al. Sensitization to foods in gastroesophageal reflux disease and its relation to eosinophils in the esophagus: is it of clinical importance? Ann Allergy Asthma Immunol 2010; 105:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/59\">",
"      Poh CH, Gasiorowska A, Navarro-Rodriguez T, et al. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. Gastrointest Endosc 2010; 71:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/60\">",
"      Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013; 108:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/61\">",
"      Hirano I, Zhang Q, Pandolfino JE, Kahrilas PJ. Four-day Bravo pH capsule monitoring with and without proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2005; 3:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/62\">",
"      Pritchett JM, Aslam M, Slaughter JC, et al. Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy. Clin Gastroenterol Hepatol 2009; 7:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/63\">",
"      Fass R, Sontag SJ, Traxler B, Sostek M. Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol 2006; 4:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/64\">",
"      Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/65\">",
"      Fass R, Murthy U, Hayden CW, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000; 14:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/66\">",
"      Watson RG, Tham TC, Johnston BT, McDougall NI. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux--the \"sensitive oesophagus\". Gut 1997; 40:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/67\">",
"      Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998; 12:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/68\">",
"      Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/69\">",
"      Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/70\">",
"      Janiak P, Thumshirn M, Menne D, et al. Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial. Aliment Pharmacol Ther 2007; 26:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/71\">",
"      Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003; 98:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/72\">",
"      Wang Y, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev 2009; :CD004275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/73\">",
"      Rackoff A, Agrawal A, Hila A, et al. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus 2005; 18:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/74\">",
"      Lidums I, Lehmann A, Checklin H, et al. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 2000; 118:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/75\">",
"      Zhang Q, Lehmann A, Rigda R, et al. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 2002; 50:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/76\">",
"      Omari TI, Benninga MA, Sansom L, et al. Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. J Pediatr 2006; 149:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/77\">",
"      Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003; 17:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/78\">",
"      Koek GH, Sifrim D, Lerut T, et al. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003; 52:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/79\">",
"      Cossentino MJ, Mann K, Armbruster SP, et al. Randomised clinical trial: the effect of baclofen in patients with gastro-oesophageal reflux - a randomised prospective study. Aliment Pharmacol Ther 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/80\">",
"      Boeckxstaens GE, Beaumont H, Hatlebakk JG, et al. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial. Gut 2011; 60:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/81\">",
"      Clouse RE, Lustman PJ, Eckert TC, et al. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology 1987; 92:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/82\">",
"      Handa M, Mine K, Yamamoto H, et al. Antidepressant treatment of patients with diffuse esophageal spasm: a psychosomatic approach. J Clin Gastroenterol 1999; 28:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/83\">",
"      Rosenthal R, Peterli R, Guenin MO, et al. Laparoscopic antireflux surgery: long-term outcomes and quality of life. J Laparoendosc Adv Surg Tech A 2006; 16:557.",
"     </a>",
"    </li>",
"    <li>",
"     Ip S, Bonis P, Tatsioni A, et al. Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease. Evidence Report/Technology Assessment No. 1. (Prepared by Tufts-New England Medical Center. Evidence-based Practice Center under Contract No. 290-02-0022.) Rockville, MD: Agency for Healthcare Research and Quality. December 2005 www.effectivehealthcare.ahrq.gov/reports/final.cfm (Accessed on March 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/85\">",
"      Ip S, Tatsioni A, Conant A, et al. Predictors of clinical outcomes following fundoplication for gastroesophageal reflux disease remain insufficiently defined: a systematic review. Am J Gastroenterol 2009; 104:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/86\">",
"      Bonavina L, DeMeester T, Fockens P, et al. Laparoscopic sphincter augmentation device eliminates reflux symptoms and normalizes esophageal acid exposure: one- and 2-year results of a feasibility trial. Ann Surg 2010; 252:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/87\">",
"      Smith CD. New developments in esophageal surgery. Gastrointest Endosc Clin N Am 2010; 20:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/88\">",
"      Ganz RA, Peters JH, Horgan S, et al. Esophageal sphincter device for gastroesophageal reflux disease. N Engl J Med 2013; 368:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/89\">",
"      Lipham JC, DeMeester TR, Ganz RA, et al. The LINX&reg; reflux management system: confirmed safety and efficacy now at 4 years. Surg Endosc 2012; 26:2944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/18/17706/abstract/90\">",
"      Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther 2007; 26:1333.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2239 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-1.234.2.38-DECD7EA589-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_18_17706=[""].join("\n");
var outline_f17_18_17706=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      UNDERLYING MECHANISMS OF PPI FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Proper dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Compliance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1992772993\">",
"      Functional heartburn and esophageal hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Weakly acidic or alkaline reflux (non-acid reflux)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Residual acid reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bile acid reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10699043\">",
"      Nocturnal acid breakthrough",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10699057\">",
"      Differences in metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1992773116\">",
"      Reduced bioavailability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10699071\">",
"      Drug resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10699078\">",
"      Delayed healing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1992772901\">",
"      Helicobacter pylori status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Psychological comorbidity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Upper endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Esophageal pH testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Esophageal impedance testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1992771420\">",
"      Esophageal manometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1992771471\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1992771493\">",
"      Optimizing therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1992771500\">",
"      Lifestyle modifications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Treatment of residual acid reflux",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1992771592\">",
"      - Adjustment of proton pump inhibitor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Bedtime H2 receptor antagonist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Treatments aimed at reducing weakly acidic reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Treatment of esophageal hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Treatment of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Surgical treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Other therapeutic approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2239\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2239|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?33/56/34703\" title=\"algorithm 1\">",
"      Management algorithm of GERD patient who failed PPI once daily",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15240?source=related_link\">",
"      Chest pain of esophageal origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=related_link\">",
"      Clinical manifestations and diagnosis of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1879?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of non-acid reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=related_link\">",
"      Diagnosis and staging of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25688?source=related_link\">",
"      Endoscopic therapy for gastroesophageal reflux disease: Sewing and full-thickness plication techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26247?source=related_link\">",
"      Esophageal multichannel intraluminal impedance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=related_link\">",
"      Etiology and diagnosis of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/46/9959?source=related_link\">",
"      Helicobacter pylori and gastroesophageal reflux disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16568?source=related_link\">",
"      Motility testing: When does it help?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=related_link\">",
"      Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13928?source=related_link\">",
"      Pathophysiology of reflux esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12263?source=related_link\">",
"      Radiofrequency treatment for gastroesophageal reflux disease (the Stretta&reg; procedure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=related_link\">",
"      Surgical management of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=related_link\">",
"      Treatment of delayed gastric emptying",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_18_17707="ADA opthalmologic exam schedule";
var content_f17_18_17707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F61833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F61833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ophthalmologic examination schedule",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Patient group",
"      </td>",
"      <td class=\"subtitle1\">",
"       Recommended first examination",
"      </td>",
"      <td class=\"subtitle1\">",
"       Minimum routine follow-up*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Type 1 diabetes",
"      </td>",
"      <td>",
"       Within 5 years after diagnosis of diabetes once patient is age 10 years or older&bull;",
"      </td>",
"      <td>",
"       Yearly",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Type 2 diabetes",
"      </td>",
"      <td>",
"       At time of diagnosis of diabetes",
"      </td>",
"      <td>",
"       Yearly",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pregnancy in preexisting diabetes",
"      </td>",
"      <td>",
"       Prior to conception and during first trimester. Counsel on the risk of development and/or progression of retinopathy.",
"      </td>",
"      <td>",
"       Close follow-up throughout pregnancy and for one year postpartum.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Abnormal findings necessitate more frequent follow-up.",
"     <br>",
"      &bull; Some evidence suggests that the prepubertal duration of diabetes may be important in the development of microvascular complications; therefore, clinical judgment should be used when applying these recommendations to individual patients.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; 2004 American Diabetes Association From Diabetes Care Vol 27, Supplement 1, 2004. Reprinted with permission from The American Diabetes Association. Modifications from Standards of Medical Care in Diabetes--2009. Diabetes Care Vol 32, Supplement 1, 2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_18_17707=[""].join("\n");
var outline_f17_18_17707=null;
var title_f17_18_17708="Treatable conditions associated with cardiac arrest";
var content_f17_18_17708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatable conditions associated with cardiac arrest",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common associated clinical settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acidosis",
"       </td>",
"       <td>",
"        Diabetes, diarrhea, drug overdose, renal dysfunction, sepsis, shock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia",
"       </td>",
"       <td>",
"        Gastrointestinal bleeding, nutritional deficiencies, recent trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac tamponade",
"       </td>",
"       <td>",
"        Post-cardiac surgery, malignancy, post-myocardial infarction, pericarditis, trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperkalemia",
"       </td>",
"       <td>",
"        Drug overdose, renal dysfunction, hemolysis, excessive potassium intake, rhabdomyolysis, major soft tissue injury, tumor lysis syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypokalemia*",
"       </td>",
"       <td>",
"        Alcohol abuse, diabetes mellitus, diuretics, drug overdose, profound gastrointestinal losses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothermia",
"       </td>",
"       <td>",
"        Alcohol intoxication, significant burns, drowning, drug overdose, elder patient, endocrine disease, environmental exposure, spinal cord disease, trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypovolemia",
"       </td>",
"       <td>",
"        Significant burns, diabetes, gastrointestinal losses, hemorrhage, malignancy, sepsis, trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoxia",
"       </td>",
"       <td>",
"        Upper airway obstruction, hypoventilation (CNS dysfunction, neuromuscular disease), pulmonary disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocardial infarction",
"       </td>",
"       <td>",
"        Cardiac arrest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poisoning",
"       </td>",
"       <td>",
"        History of alcohol or drug abuse, altered mental status, classic toxidrome (eg, sympathomimetic), occupational exposure, psychiatric disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary embolism",
"       </td>",
"       <td>",
"        Immobilized patient, recent surgical procedure (eg, orthopedic), peripartum, risk factors for thromboembolic disease, recent trauma, presentation consistent with acute pulmonary embolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tension pneumothorax",
"       </td>",
"       <td>",
"        Central venous catheter, mechanical ventilation, pulmonary disease (eg, asthma, chronic obstructive pulmonary disease), thoracentesis, thoracic trauma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Hypomagnesemia should be assumed in the setting of hypokalemia, and both should be treated.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Eisenberg MS, Mengert TJ. Cardiac resuscitation. N Engl J Med 2001; 344:1304.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_18_17708=[""].join("\n");
var outline_f17_18_17708=null;
var title_f17_18_17709="Potassium adaptation";
var content_f17_18_17709=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Increased potassium secretion in potassium adaptation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 215px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relationship between the plasma potassium concentration (which is raised by potassium chloride infusion) and distal potassium secretion in normal animals (dashed line) and those treated with a high-potassium diet for four weeks (solid line). A high-potassium diet leads to potassium adaptation: at any plasma potassium concentration, distal potassium secretion is two to four times higher in adapted animals compared to normals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Stanton BA. Am J Physiol 1989; 257:R989.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_18_17709=[""].join("\n");
var outline_f17_18_17709=null;
var title_f17_18_17710="R-ICE recipe";
var content_f17_18_17710=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) chemotherapy for diffuse large B-cell lymphoma",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 14 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Rituximab",
"        </strong>",
"       </td>",
"       <td>",
"        375 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in normal saline (NS) or 5 percent dextrose in water (D5W) to a final concentration of 1 to 4 mg/mL. Initial infusion: start at 50 mg/hour; escalate in 50 mg/hour increments every 30 minutes to a maximum of 400 mg/hour, as tolerated",
"        <sup>",
"         [2]",
"        </sup>",
"        . For subsequent infusions, administer 20 percent of the total dose over the first 30 minutes and the remaining 80 percent over 60 minutes, as tolerated. The 90-minute infusion schedule should NOT be used in patients who have clinically significant cardiovascular disease or have a circulating lymphocyte count &ge;5000/mm",
"        <sup>",
"         3",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Day minus 2 of cycle 1 (48 hours prior to initiation of cycle 1), then day 1 of cycles 1 to 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Ifosfamide",
"        </strong>",
"       </td>",
"       <td>",
"        5000 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        continuous IV infusion",
"       </td>",
"       <td>",
"        Dilute in 0.9 percent sodium chloride injection or D5W to a final concentration of 0.6 to 20 mg/mL and infuse over 24 hours.",
"       </td>",
"       <td>",
"        Day 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Mesna",
"        </strong>",
"        *",
"       </td>",
"       <td>",
"        5000 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        continuous IV infusion",
"       </td>",
"       <td>",
"        Add to ifosfamide bag and administer over 24 hours. Total concentration of mesna should not exceed 20 mg/mL.",
"       </td>",
"       <td>",
"        Day 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Carboplatin",
"        </strong>",
"       </td>",
"       <td>",
"        AUC",
"        <sup>",
"         &Delta;",
"        </sup>",
"        = 5 mg/mL x min IV (maximum dose = 800 mg)",
"       </td>",
"       <td>",
"        Dilute in 250 mL 0.9 percent sodium chloride injection and administer over 30 minutes.",
"       </td>",
"       <td>",
"        Day 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Etoposide",
"        </strong>",
"       </td>",
"       <td>",
"        100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV daily",
"       </td>",
"       <td>",
"        Dilute in 500 mL 0.9 percent sodium chloride injection or D5W to final concentration &lt;0.4 mg/mL. Infuse over 30 to 60 minutes; if infused more rapidly, severe hypotension may occur.",
"       </td>",
"       <td>",
"        Days 3 to 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MODERATE (30 to 90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Premedicate with acetaminophen and diphenhydramine, with or without an H2 blocker, 30 minutes prior to at least the first and second infusions of rituximab",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with G-CSF indicated",
"        <sup>",
"         [1]",
"        </sup>",
"        . Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Adjustment of initial etoposide and ifosfamide doses may be needed for preexisting renal or liver dysfunction",
"        <sup>",
"         [3,4]",
"        </sup>",
"        . Carboplatin dose is calculated based upon renal function; dose adjustment is not necessary for liver dysfunction",
"        <sup>",
"         [5]",
"        </sup>",
"        . Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hepatitis screening:",
"        </strong>",
"        Patients should be screened for hepatitis B and C prior to starting rituximab, and if positive, considered for hepatitis B prophylaxis. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", \"Overview of the management of hepatitis B and case examples\", section on Who should be tested? and \"Hepatitis B virus reactivation associated with immunosuppression\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess basic metabolic panel (creatinine and electrolytes) daily during treatment and prior to each subsequent treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assay for liver function prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Dipstick urine for hematuria daily, on days 4 and 5.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Carriers of hepatitis B or C should be monitored for clinical and laboratory signs of active infection during and following completion of therapy. Rituximab should be discontinued if reactivation occurs. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose modifications for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Delay treatment cycle until the absolute neutrophil count is greater than 1000/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelet count is greater than 50,000/mm",
"        <sup>",
"         3[1]",
"        </sup>",
"        . Dose reduction not indicated for intracycle hematologic toxicity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; G-CSF: granulocyte-colony stimulating factors; CBC: complete blood count; GFR: glomerular filtration rate.",
"     <br/>",
"     * Due to a longer half-life of ifosfamide and associated metabolites at higher doses, some references recommend continuation of mesna for 12 to 24 hours beyond completion of ifosfamide to reduce the risk of hemorrhagic cystitis. If necessary, oral mesna may be used at a dose twice that of IV mesna.",
"     <br/>",
"     &Delta; AUC (area under the concentration X time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert formula is total dose (mg) = (target AUC) x (GFR + 25). Refer to UpToDate topic on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Kewalramani T, et al. Blood 2004; 103:3684.",
"      </li>",
"      <li>",
"       Rituxan (rituximab) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed October 23, 2012).",
"      </li>",
"      <li>",
"       IFEX (ifosfamide) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed October 23, 2012).",
"      </li>",
"      <li>",
"       Toposar (etoposide) injection. US FDA-approved package insert US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed October 23, 2012).",
"      </li>",
"      <li>",
"       Carboplatin injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on October 23, 2012).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_18_17710=[""].join("\n");
var outline_f17_18_17710=null;
var title_f17_18_17711="Systolic BP cardiovascular events HOT trial";
var content_f17_18_17711=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55532%7ENEPH%2F81362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55532%7ENEPH%2F81362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Systolic pressure and cardiovascular events in HOT trial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 322px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Estimated incidence (95 percent CI) of major cardiovascular events in relation to achieved mean systolic blood pressure in the HOT trial. The systolic pressure at the lowest point of the curve is indicated (minimum).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hansson, L, Zanchetti, A, Carruthers, SG, et al, Lancet 1998; 351:1755.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diastolic pressure and cardiovascular events in HOT trial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 333px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Estimated incidence (95 percent CI) of major cardiovascular events in relation to achieved mean diastolic blood pressure in the HOT trial. The diastolic pressure at the lowest point of the curve is indicated (minimum).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hansson, L, Zanchetti, A, Carruthers, SG, et al, Lancet 1998; 351:1755.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_18_17711=[""].join("\n");
var outline_f17_18_17711=null;
